**Zinc Supplementation and Prostate Cancer**

Wong Pooi-Fong1 and AbuBakar Sazaly2

*1Department of Pharmacology 2Department of Medical Microbiology Faculty of Medicine, University of Malaya Malaysia* 

#### **1. Introduction**

422 Prostate Cancer – From Bench to Bedside

Masters, J.R., Kane, C., Yamamoto, H., & Ahmed, A. (2008). Prostate Cancer Stem Cell

Miki, J. & Rhim, J.S. (2008). Prostate Cell Cultures as in vitro Models for the Study of Normal

Mimeault, M., Hauke, R., Mehta, P.P., & Batra, S.K. (2007). Recent Advances in Cancer

Musumeci, M., Coppola, V., Addario, A., Patrizii, M., Maugeri-Saccà, M., Memeo, L.,

Okada, H., Kohanbash, G., & Lotze, M.T. (2010). MicroRNAs in Immune Regulation:

Ozen, M., Creighton, C.J., Ozdemir, M., Ittmann, M. (2008). Widespread deregulation of

Peng, X., Guo, W., Liu, T., Wang, X., Tu, X., Xiong, D., Chen, S., Lai, Y., Du, H., Chen, G.,

Sevli, S., Uzumcu, A., Solak, M., Ittman, M., & Ozen, M. (2010). The Function of MiRNAs,

Schaefer, A., Jung, M., Mollenkopf, H.J., Wagner, I., Stephan, C., Jentzmik, F., Miller, K.,

Suzuki, H.I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., & Miyazono, K. (2009).

Tang, X., Tang, X., Gal, J., Kyprianou, N., Zhu, H., & Tang, G. (2011). Detection of

Tong, A.W., Fulgham, P., Jay, C., Chen, P., Khalil, I., Liu, S., Senzer, N., Eklund, A.C., Han,

Wang, Z.A. & Shen, M.M. (2011). Revisiting the Concept of Cancer Stem Cells in Prostate

Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M.,

*Medicine,* Vol.11, No.5, (September-October, 2007), pp. 981-1011,

*and Cell Biology,* Vol.42, No.8, (August, 2010), pp. 1256-1261,

Regulation of EMT. *PLOS One,* Vol.6, No.5, (May 2011), e20341,

*Prostatic Diseases,* Vol.13, No.3, (September 2010), pp. 208-217,

*Cancer Gene Therapy,* Vol.16, No.3, (March, 2009), pp.206-216,

Cancer. *Oncogene,* Vol.30, No.11, (March, 2011), pp. 1261-1271,

(December 2008), pp. 316-319,

No.1, (March 2008), pp. 32-39,

2008), pp. 1788-1793,

pp. 529-533,

*Oncogene*, (May, 2011), Epub ahead of print,

Vol.126, No.5, (March, 2010), pp. 1166-1176,

*Biology,* Vol.732, No.1, (2011), pp. 69-88,

No.7, (February, 2006), pp. 2257-2261,

Therapy: Hype or Hope?. *Prostate Cancer and Prostatic Diseases,* Vol.11, No.4,

Stem Cells and Cancer Stem Cells. *Prostate Cancer and Prostatic Diseases,* Vol.11,

Stem/Progenitor Cell Research: Therapeutic Implications for Overcoming Resistance to the Most Aggressive Cancers. *Journal of Cellular and Molecular* 

Colarossi, C., Francescangeli, F., Biffoni, M., Collura, D., Giacobbe, A., D'Urso, L., Falchi, M., Venneri, M.A., Muto, G., De Maria, R., & Bonci, D. (2011). Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer.

Opportunities for Cancer Immunotherapy. *The International Journal of Biochemistry* 

microRNA expression in human prostate cancer. *Oncogene,* Vol.27, No.12, (March

Liu, G., Tang, Y., Huang, S., & Zou, X. (2011). Identification of miRs-143 and -145 that Is Associated with Bone Metastasis of Prostate Cancer and Involved in the

the Small but Potent Molecules, in Human Prostate Cancer. *The Prostate Cancer and* 

Lein, M., Kristiansen, G., & Jung, K. (2010). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. *International Journal of Cancer,* 

Modulation of microRNA processing by p53. *Nature,* Vol.460, No.7254, (July, 2009),

microRNAs in prostate cancer cells by microRNA array. *Methods in Molecular* 

J., & Nemunaitis, J. (2009). MicroRNA profile analysis of human prostate cancers.

Roldo, C., Ferracin, M., Prueitt, R.L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C.C., Croce, C.M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America,* Vol.103, Prostate cancer continues to be one of the most common fatal cancers in men (Jemal et al., 2010). The comprehensive understanding of the etiology of this disease is however, far from complete because of multitude of genetics and environmental factors involved in the development of this disease (Deutsch et al., 2004; Giovannucci, 2001). One characteristic feature of the prostate gland is its unique ability to accumulate high concentrations of zinc, which may otherwise be toxic to other tissues (Costello & Franklin, 1998). For reasons primarily still unknown, cancerous prostate cells somehow lose its ability to accumulate intracellular zinc concentrations. This is based on consistent observations of low zinc concentrations in malignant prostate tissues as compared to normal prostate and benign prostatic hyperplasia tissues (Feustel & Wennrich, 1984; Ho, 2004; Vartsky et al., 2003; Zaichick et al., 1997). These findings thereby, imply a potential importance of zinc in the pathogenesis of prostate cancer.

It is suggested that dietary zinc supplementation protects against oxidative damage, reduces cancer risk (Ho, 2004) and has therapeutic potentials against prostate cancer (Franklin & Costello, 2007). Epidemiologic studies, however, provided contradictory findings on the effectiveness of zinc in prevention against prostate cancer. While there are studies that showed zinc reduces the risk of developing prostate cancer (Key et al., 1997; Kristal et al., 1999), others showed that advanced prostate cancer is associated with high intake of zinc and potentiate the development of benign prostate hyperplasia (BPH) and progression towards cancer (Gallus et al., 2007; Lagiou et al., 1999; Lawson et al., 2007; Leitzmann et al., 2003; Moyad, 2004). Various mechanisms have been proposed to explain how high zinc regulates prostate health and indirectly, how its absence or low concentration could have contributed to the occurrence of prostate cancer. Restoration of high zinc to cancerous prostate tissues has been shown to inhibit prostate cancer cells proliferation (Feng et al., 2002; Feng et al., 2000; Iguchi et al., 1998; Liang et al., 1999) and invasion (Ishii et al., 2004; Ishii et al., 2001a; Ishii et al., 2001b; Uzzo et al., 2006). In contrast, there are studies which showed that zinc under nonphysiological conditions could promote cancer cell growth and invasion (Boissier et al., 2000; Nemoto et al., 2000; Wong & Abubakar, 2008a; Wong & Abubakar, 2010).

Because of the diverse roles of zinc in cell signaling, the exact pathways and genes affected by the absence or presence of high zinc concentrations in prostate cancer cells remain unraveled. In an attempt to further understand the complexicity of the role of zinc in prostate cancer, this

Zinc Supplementation and Prostate Cancer 425

bound to high molecular weight ligands such as metalloenzymes, metalloproteins, nucleoproteins and nucleic acids. The remaining 10% of zinc is readily exchangeable and loosely bound to amino acid and citrate (Frederickson, 1989; Outten & O'Halloran, 2001). This pool of zinc is found in plasma, liver and bone and is metabolically active, rapidly exchanged and sensitive to changes in the bioavailability of zinc in the diet. The prostate gland, pancreas, adrenal gland, certain areas of the brain, inner ear and eye, skin, nails, hair, red and white blood cells are known to accumulate high concentrations of zinc (Tapiero &

The concentrations of zinc are strictly regulated *in vivo* because dysregulation of zinc homeostasis can result in pathogenic consequences. Approximately 30-40% of intracellular zinc is localized in the nucleus, 50% in the cytosol and cytosolic organelles and the remainder are associated with cell membranes (Vallee & Falchuk, 1993). Zinc transporters play important roles in maintaining zinc homeostasis, as zinc ions are hydrophilic and do not cross cell membranes by passive diffusion (Cousins & McMahon, 2000). There are two known families of zinc transporters i.e. the ZIP (Zrt/Irt-like proteins (SLC39A)) family and the cation diffusion facilitator/Zinc transporter (CDF/ZnT (SLC30A)) family. At least 15 members of the ZIP family (Zn2+-regulated metal transporter) (Cousins et al., 2006) and 10 members from the ZnT family (Eide, 2004) are found in mammalian cells. ZnT transporters regulate zinc efflux from cells or into intracellular vesicles, hence, reduce intracellular zinc availability, whereas ZIP members of the ZIP family participate in the transport of zinc, iron, and/or manganese. The human ZIP1, ZIP2, and ZIP4 proteins are involved in zinc uptake

Zinc has structural, catalytic and regulatory functions. It is a structural element found in many enzymes essential for DNA synthesis, transcription, aminoacyl-tRNA synthesis and ribosomal functions. It is found in zinc finger motifs of more than two thousands of transcription factors where these motifs provide a platform for interaction with DNA or other proteins (Vallee et al., 1991). Zincs are also found in LIM domains in proteins important for cytoskeletal organization, organ development and oncogenesis (Kadrmas & Beckerle, 2004). Zinc regulates cell proliferation and differentiation by modulating nucleic acid metabolisms and protein synthesis. It also controls cell growth by activating, transporting and modulating growth hormone, insulin-like growth factor-1, prolactin, testosterone and other steroid hormones (Costello et al., 1999; Ozturk et al., 2005; Prasad et al., 1996; Turgut et al., 2005). Zinc, unlike the highly reactive copper and iron, does not participate in redox reactions (Berg & Shi, 1996). The incorporation of zinc into proteins instead of these highly reactive elements helps prevent the generation of free radicals (Ho, 2004). Zinc, hence, has anti-oxidant activities. It maintains proper folding, stability and activity of zinc-dependent enzymes by protecting these enzymes from free radicals attacks (Coleman, 1992). Some of the zinc-dependent enzymes include superoxide dismutase, carbonic anhydrase, alkaline phosphatase, glutamic dehydrogenase, nucleotidase, carboxypeptidase A, retinal dehydrogenase and angiotensin-converting enzymes. Intracellular zinc also protects several compounds from oxidative damage and these include citrate in the prostate gland (Omu et al., 1998) and insulin in the secretory granules of the islet beta cells (Zalewski et al., 1994). In addition, zinc exerts its anti-oxidant abilities

across the plasma membrane of various cell types (Eide, 2004).

**4. Major functions of zinc** 

**4.1 Structural and catalytic functions** 

Tew, 2003).

chapter will discuss issues related to the regulatory roles of zinc in normal prostate, the consequences of losing this regulatory role in the malignant cells and the implications of zinc supplementation in the cancer cells.

### **2. Zinc and human health**

Zinc is an essential trace element, critical for diverse biological functions in the human body. Its importance in humans was not discovered until 1961 where zinc deficiency was found to be the cause of growth retardation and hypogonadism in Iranian and Egyptian patients (Prasad et al., 1961; Prasad et al., 1963). Meat, poultry, oyster, dairy products, legumes and cereals are food rich in zinc. However, phytates, which are present in some cereals and legumes can reduce the bioavailability of zinc by inhibiting absorption of zinc in the intestines (Sandstrom, 1997; Wise, 1995). The recommended dietary allowance (RDA) for daily intake of zinc in 97- 98% healthy individuals is 8 mg/d for women, 11 mg/d for men, 11-12 mg/ml for pregnant and lactating women. Children from 1-3 years old, 4-8 years and 9-13 years old require 3, 5 and 8 mg/d of zinc, respectively (Food and Nutritional Board of Medicine, 2010a). The tolerable upper intake level (UL), defined as the maximal daily intake unlikely to cause adverse health effects is 40 mg/d for adults. For children of 1-3, 4-8 and 9-13 years old, ULs are 7 mg/d, 12 and 23 mg/d, respectively, (Food and Nutritional Board of Medicine, 2010b).

Deficiency of zinc is associated with significant health problems. Early manifestations of zinc deficiency include decreased immunity resulting in increased susceptibility to infections such as diarrhea, common cold, acute lower respiratory infection and malaria. Zinc-deficient individuals also display dermatitis, delayed wound healing and alopecia. Prolonged deficiency leads to retardation of growth, genital development, hypogonadism and impaired neuropsychological functions (Prasad, 2008). Zinc deficiency in pregnancy retards fetal growth and postnatal development, causes neural tube defects and premature birth but the use of zinc supplementation in women still requires further studies (Osendarp et al., 2003; Uriu-Adams & Keen, 2010).

Zinc supplements are found in the forms of zinc gluconate, zinc sulfate, and zinc acetate, where the percentage of elemental zinc can varies (Haase et al., 2008). Studies have shown that supplementation with zinc corrects growth and gonadal development, improves immune functions and hastens recovery from diarrhea, common cold, acute lower respiratory infection and malaria (Black, 2003; Fischer Walker & Black, 2004). It is also used to treat genetic disorders such as acrodermatitis enteropathica (Maverakis et al., 2007) and Wilson's disease (Brewer, 2001). Zinc excess can induce copper deficiency and it is used in Wilson's disease to interfere with uptake of copper and subsequently reduce excessive copper accumulation. While zinc supplementation may be beneficial in certain conditions excessive zinc intake can pose serious health risks. Acute zinc toxicity causes gastrointestinal-related symptoms such nausea, vomiting, tenesmus and diarrhea (Brown et al., 1964). Chronic zinc toxicity can lead to copper deficiency and its related hematological and neurological manifestations (Maret & Sandstead, 2006). Chronic high intake of zinc can also cause abnormalities of genitourinary functions (Johnson et al., 2007).

#### **3. Zinc homeostasis and transport**

Total zinc in human body is about 2-3 g for a 70 kg adult (Wastney et al., 1986). Ninety percent is incorporated in the muscle, most of which are poorly exchangeable and tightly

chapter will discuss issues related to the regulatory roles of zinc in normal prostate, the consequences of losing this regulatory role in the malignant cells and the implications of zinc

Zinc is an essential trace element, critical for diverse biological functions in the human body. Its importance in humans was not discovered until 1961 where zinc deficiency was found to be the cause of growth retardation and hypogonadism in Iranian and Egyptian patients (Prasad et al., 1961; Prasad et al., 1963). Meat, poultry, oyster, dairy products, legumes and cereals are food rich in zinc. However, phytates, which are present in some cereals and legumes can reduce the bioavailability of zinc by inhibiting absorption of zinc in the intestines (Sandstrom, 1997; Wise, 1995). The recommended dietary allowance (RDA) for daily intake of zinc in 97- 98% healthy individuals is 8 mg/d for women, 11 mg/d for men, 11-12 mg/ml for pregnant and lactating women. Children from 1-3 years old, 4-8 years and 9-13 years old require 3, 5 and 8 mg/d of zinc, respectively (Food and Nutritional Board of Medicine, 2010a). The tolerable upper intake level (UL), defined as the maximal daily intake unlikely to cause adverse health effects is 40 mg/d for adults. For children of 1-3, 4-8 and 9-13 years old, ULs are 7 mg/d, 12

Deficiency of zinc is associated with significant health problems. Early manifestations of zinc deficiency include decreased immunity resulting in increased susceptibility to infections such as diarrhea, common cold, acute lower respiratory infection and malaria. Zinc-deficient individuals also display dermatitis, delayed wound healing and alopecia. Prolonged deficiency leads to retardation of growth, genital development, hypogonadism and impaired neuropsychological functions (Prasad, 2008). Zinc deficiency in pregnancy retards fetal growth and postnatal development, causes neural tube defects and premature birth but the use of zinc supplementation in women still requires further studies (Osendarp

Zinc supplements are found in the forms of zinc gluconate, zinc sulfate, and zinc acetate, where the percentage of elemental zinc can varies (Haase et al., 2008). Studies have shown that supplementation with zinc corrects growth and gonadal development, improves immune functions and hastens recovery from diarrhea, common cold, acute lower respiratory infection and malaria (Black, 2003; Fischer Walker & Black, 2004). It is also used to treat genetic disorders such as acrodermatitis enteropathica (Maverakis et al., 2007) and Wilson's disease (Brewer, 2001). Zinc excess can induce copper deficiency and it is used in Wilson's disease to interfere with uptake of copper and subsequently reduce excessive copper accumulation. While zinc supplementation may be beneficial in certain conditions excessive zinc intake can pose serious health risks. Acute zinc toxicity causes gastrointestinal-related symptoms such nausea, vomiting, tenesmus and diarrhea (Brown et al., 1964). Chronic zinc toxicity can lead to copper deficiency and its related hematological and neurological manifestations (Maret & Sandstead, 2006). Chronic high intake of zinc can also cause abnormalities of genitourinary

Total zinc in human body is about 2-3 g for a 70 kg adult (Wastney et al., 1986). Ninety percent is incorporated in the muscle, most of which are poorly exchangeable and tightly

and 23 mg/d, respectively, (Food and Nutritional Board of Medicine, 2010b).

supplementation in the cancer cells.

et al., 2003; Uriu-Adams & Keen, 2010).

functions (Johnson et al., 2007).

**3. Zinc homeostasis and transport** 

**2. Zinc and human health** 

bound to high molecular weight ligands such as metalloenzymes, metalloproteins, nucleoproteins and nucleic acids. The remaining 10% of zinc is readily exchangeable and loosely bound to amino acid and citrate (Frederickson, 1989; Outten & O'Halloran, 2001). This pool of zinc is found in plasma, liver and bone and is metabolically active, rapidly exchanged and sensitive to changes in the bioavailability of zinc in the diet. The prostate gland, pancreas, adrenal gland, certain areas of the brain, inner ear and eye, skin, nails, hair, red and white blood cells are known to accumulate high concentrations of zinc (Tapiero & Tew, 2003).

The concentrations of zinc are strictly regulated *in vivo* because dysregulation of zinc homeostasis can result in pathogenic consequences. Approximately 30-40% of intracellular zinc is localized in the nucleus, 50% in the cytosol and cytosolic organelles and the remainder are associated with cell membranes (Vallee & Falchuk, 1993). Zinc transporters play important roles in maintaining zinc homeostasis, as zinc ions are hydrophilic and do not cross cell membranes by passive diffusion (Cousins & McMahon, 2000). There are two known families of zinc transporters i.e. the ZIP (Zrt/Irt-like proteins (SLC39A)) family and the cation diffusion facilitator/Zinc transporter (CDF/ZnT (SLC30A)) family. At least 15 members of the ZIP family (Zn2+-regulated metal transporter) (Cousins et al., 2006) and 10 members from the ZnT family (Eide, 2004) are found in mammalian cells. ZnT transporters regulate zinc efflux from cells or into intracellular vesicles, hence, reduce intracellular zinc availability, whereas ZIP members of the ZIP family participate in the transport of zinc, iron, and/or manganese. The human ZIP1, ZIP2, and ZIP4 proteins are involved in zinc uptake across the plasma membrane of various cell types (Eide, 2004).

## **4. Major functions of zinc**

#### **4.1 Structural and catalytic functions**

Zinc has structural, catalytic and regulatory functions. It is a structural element found in many enzymes essential for DNA synthesis, transcription, aminoacyl-tRNA synthesis and ribosomal functions. It is found in zinc finger motifs of more than two thousands of transcription factors where these motifs provide a platform for interaction with DNA or other proteins (Vallee et al., 1991). Zincs are also found in LIM domains in proteins important for cytoskeletal organization, organ development and oncogenesis (Kadrmas & Beckerle, 2004). Zinc regulates cell proliferation and differentiation by modulating nucleic acid metabolisms and protein synthesis. It also controls cell growth by activating, transporting and modulating growth hormone, insulin-like growth factor-1, prolactin, testosterone and other steroid hormones (Costello et al., 1999; Ozturk et al., 2005; Prasad et al., 1996; Turgut et al., 2005). Zinc, unlike the highly reactive copper and iron, does not participate in redox reactions (Berg & Shi, 1996). The incorporation of zinc into proteins instead of these highly reactive elements helps prevent the generation of free radicals (Ho, 2004). Zinc, hence, has anti-oxidant activities. It maintains proper folding, stability and activity of zinc-dependent enzymes by protecting these enzymes from free radicals attacks (Coleman, 1992). Some of the zinc-dependent enzymes include superoxide dismutase, carbonic anhydrase, alkaline phosphatase, glutamic dehydrogenase, nucleotidase, carboxypeptidase A, retinal dehydrogenase and angiotensin-converting enzymes. Intracellular zinc also protects several compounds from oxidative damage and these include citrate in the prostate gland (Omu et al., 1998) and insulin in the secretory granules of the islet beta cells (Zalewski et al., 1994). In addition, zinc exerts its anti-oxidant abilities

Zinc Supplementation and Prostate Cancer 427

regulate intracellular zinc concentrations (Langmade et al., 2000). Other zinc finger transcription factors such as Egr-1, AP-1 and NF-B are important for the regulation of genes that control cells proliferation. Deregulation of these transcription factors contributes to cancer cells proliferation, metastasis and angiogenesis. How zinc affects the regulation of these transcription factors and their outcomes, however, varies. It is shown in a number of studies, that zinc at different concentrations activate or suppress the activities of NF-B in different cell lines resulting in different cellular responses (Kim et al., 2007; Uzzo et al., 2006;

Zinc modulates kinases and phosphatases of major cells signaling pathways. A number of studies showed that zinc stimulates EGF receptor phosphorylation and activates members of the MAPKs family such as ERK (Hansson, 1996; Klein et al., 2006; Samet et al., 1998; Uzzo et al., 2006) and p38 kinase (Huang et al., 1999; Wu et al., 1999; Wu et al., 2005) activities in prostate cancer cells, murine fibroblasts, human bronchial epithelial cells, human airway epithelial cells and mouse cortical cells. Zinc also induces the phosphorylation of p70S6 kinase in murine fibroblasts, c-jun N-terminal kinase (JNK) in mouse cortical cells through phosphatidylinositol 3-kinase (P13K) signaling pathway (Eom et al., 2001; Kim et al., 2000), protein kinase C (PKC) activation (Csermely et al., 1988), protein kinase B (PKB) and glycogen synthase kinase (GSK)-3 activities in neuroblastoma cells (An et al., 2005). A number of studies also described the role of zinc in the modulation of phosphatases. Treatment of the human airway epithelial cells and C6 rat glioma cells with zinc increased protein tyrosine phosphorylation by inhibiting phosphatases such as PTP1B and SHP-1 (Haase & Maret, 2005) and zinc also inhibits the dual-specificity phosphatase VHR (Kim et al., 2000). These findings illustrate the extensive involvement of zinc on cellular signaling pathways and genes transcription. Balanced zinc homeostasis, therefore is vital for normal cell growth and differentiation; and deviations from optimal zinc levels may contribute to pathophysiologic consequences observed in many zinc-related diseases. Most of these zincaffected pathways are also deregulated in many types of cancer and this further highlights

The human prostate gland is divided into three distinct morphological regions which include the peripheral, central and transition zones (McNeal, 1981). The peripheral zone contains the majority of the glandular tissues present in the normal prostate and accounts for 70% of the volume in the young adult prostate. The central zone consists of larger acini and has a more complex ductal branching while the transition zone comprises of glands lobules with shorter ducts in comparison to those in the peripheral zone. The central and

The normal peripheral zone of the prostate gland accumulates the highest concentrations of zinc in comparison to other soft tissues of the body (Kar & Chowdhury, 1966; Lahtonen, 1985). The ability to accumulate zinc in the peripheral zone is due to the presence of highly specialized secretory epithelial cells that is not found in the central zone of the prostate. hZIP1 transporter is an important transporter for uptake from the circulation and accumulation in the prostate gland (Costello et al., 1999; Desouki et al., 2007) while hZIP-2

hZIP1 transporters are downregulated in adenocarcinoma cells and in prostate intraepithelial neoplastic loci (PIN) (Rishi et al., 2003). This causes not only a decrease in zinc

transition zones account for 25% and 5% of the prostate volume, respectively.

and hZIP-3 retain zinc in the cellular compartment (Desouki et al., 2007).

Uzzo et al., 2002).

the importance of zinc homeostasis in oncogenesis.

**5. Zinc and the prostate gland** 

indirectly by maintaining an adequate level of the free radical scavengers such as metallothioneins (MTs) (Prasad, 1993; Tapiero & Tew, 2003). It also stabilizes cell membrane structure such as that of the red blood cells (Hennig et al., 1996) and sperm cells (Omu et al., 1998). Zinc-bound melanin granules of the skin, choroids, iris, retina, photoreceptors of the eye also provide protection against oxidative damage and apoptosis (Borovansky, 1994).

#### **4.2 Zinc and immunity**

Zinc is critical for immune function and is involved in many aspects of the immune system (Shankar & Prasad, 1998). Deficiency of zinc causes dysfunction of cells involved in innate immunity such as macrophages, neutrophils and natural killer (NK) cells and affects phagocytosis, intracellular killing, cytokine production, complement activity and delayedtype hypersensitivity. Zinc is also important for gene regulation in T lymphocytes. It activates pituitary growth hormone and thymulin, the thymic hormone that stimulates division, differentiation and maturation of T-cells, lymphocyte proliferation and cytotoxic activity of natural killer cells (Baum et al., 2000; Prasad, 1998). It also modulates the function of T-helper cells by regulating lymphokines, interleukin-2 (IL-2), interferon-gamma (IFN-) and tumour necrosis factor-alpha (TNF-) in response to invasion of pathogens (Baum et al., 2000). It is also known that zinc helps in tissue repair and wound healing by stimulating keratinocyte proliferation and migration to the injured area (Tenaud et al., 2000) and scavenges proinflammatory cytokines-produced nitric oxide to prevent tissue damage (Yamaoka et al., 2000).

#### **4.3 Zinc in cell signaling**

Zinc is involved in many aspects of cell signaling, ranging from signal recognition, second messenger metabolisms to the regulation of gene expressions. It regulates signaling processes by directly modulating the activities of kinases, phosphatases, and transcription factors (Beyersmann & Haase, 2001) or acting on its own as an intracellular secondary messenger (Fukada et al., 2011; Yamasaki et al., 2007). Zinc initiates the signaling cascades by stimulating the activation of several receptors and ion channels and these include epidermal growth factor receptor (EGF-R) (Wu et al., 1999); insulin growth factor-1 receptor (IGF-1-R) (Haase & Maret, 2005); Gamma-AminoButyric Acid (GABA) receptor (Parviz & Gross, 2007); N-methyl-D-aspartate (NMDA) channels of the neuronal cells (Smart et al., 2004); voltage-gated Ca2+ (Magistretti et al., 2003), the calcium permeable -amino-3 hydroxy-5-methyl-4-isoxazole-propionate (AMPA) channels (Blakemore & Trombley, 2004), transient receptor potential ankyrin (Hu et al., 2009) and ATP-sensitive K+ channels (Prost et al., 2004). It also affects the activities of several second messengers. It is shown that zinc inhibits cyclic adenosine monophosphate (cAMP) signaling (Klein et al., 2002) and elevates cyclic guanosine monophosphate (cGMP) levels (Watjen et al., 2001).

Zinc regulates the transcription of genes important for cell proliferation and differentiation by modulating transcription factors such as metal response element-binding transcription factor-1, MTF-1 (Langmade et al., 2000); Egr-1 (Adamson et al., 2003); AP-1 and NF-B (Herbein et al., 2006; Uzzo et al., 2006); Jun and ATF-2 (Samet et al., 1998). Among these, MTF-1 to date is the best-characterized zinc-activated transcription factors. MTF-1 responds acutely to changes in intracellular zinc concentrations by binding with zinc and translocates to nucleus. It then activates genes transcription by binding to promoters of other known zinc-responsive genes such as metallothioneins (MTs) and zinc transporter, ZnT-1 that

indirectly by maintaining an adequate level of the free radical scavengers such as metallothioneins (MTs) (Prasad, 1993; Tapiero & Tew, 2003). It also stabilizes cell membrane structure such as that of the red blood cells (Hennig et al., 1996) and sperm cells (Omu et al., 1998). Zinc-bound melanin granules of the skin, choroids, iris, retina, photoreceptors of the eye also provide protection against oxidative damage and apoptosis (Borovansky, 1994).

Zinc is critical for immune function and is involved in many aspects of the immune system (Shankar & Prasad, 1998). Deficiency of zinc causes dysfunction of cells involved in innate immunity such as macrophages, neutrophils and natural killer (NK) cells and affects phagocytosis, intracellular killing, cytokine production, complement activity and delayedtype hypersensitivity. Zinc is also important for gene regulation in T lymphocytes. It activates pituitary growth hormone and thymulin, the thymic hormone that stimulates division, differentiation and maturation of T-cells, lymphocyte proliferation and cytotoxic activity of natural killer cells (Baum et al., 2000; Prasad, 1998). It also modulates the function of T-helper cells by regulating lymphokines, interleukin-2 (IL-2), interferon-gamma (IFN-) and tumour necrosis factor-alpha (TNF-) in response to invasion of pathogens (Baum et al., 2000). It is also known that zinc helps in tissue repair and wound healing by stimulating keratinocyte proliferation and migration to the injured area (Tenaud et al., 2000) and scavenges proinflammatory cytokines-produced nitric oxide to prevent tissue damage

Zinc is involved in many aspects of cell signaling, ranging from signal recognition, second messenger metabolisms to the regulation of gene expressions. It regulates signaling processes by directly modulating the activities of kinases, phosphatases, and transcription factors (Beyersmann & Haase, 2001) or acting on its own as an intracellular secondary messenger (Fukada et al., 2011; Yamasaki et al., 2007). Zinc initiates the signaling cascades by stimulating the activation of several receptors and ion channels and these include epidermal growth factor receptor (EGF-R) (Wu et al., 1999); insulin growth factor-1 receptor (IGF-1-R) (Haase & Maret, 2005); Gamma-AminoButyric Acid (GABA) receptor (Parviz & Gross, 2007); N-methyl-D-aspartate (NMDA) channels of the neuronal cells (Smart et al., 2004); voltage-gated Ca2+ (Magistretti et al., 2003), the calcium permeable -amino-3 hydroxy-5-methyl-4-isoxazole-propionate (AMPA) channels (Blakemore & Trombley, 2004), transient receptor potential ankyrin (Hu et al., 2009) and ATP-sensitive K+ channels (Prost et al., 2004). It also affects the activities of several second messengers. It is shown that zinc inhibits cyclic adenosine monophosphate (cAMP) signaling (Klein et al., 2002) and elevates

Zinc regulates the transcription of genes important for cell proliferation and differentiation by modulating transcription factors such as metal response element-binding transcription factor-1, MTF-1 (Langmade et al., 2000); Egr-1 (Adamson et al., 2003); AP-1 and NF-B (Herbein et al., 2006; Uzzo et al., 2006); Jun and ATF-2 (Samet et al., 1998). Among these, MTF-1 to date is the best-characterized zinc-activated transcription factors. MTF-1 responds acutely to changes in intracellular zinc concentrations by binding with zinc and translocates to nucleus. It then activates genes transcription by binding to promoters of other known zinc-responsive genes such as metallothioneins (MTs) and zinc transporter, ZnT-1 that

cyclic guanosine monophosphate (cGMP) levels (Watjen et al., 2001).

**4.2 Zinc and immunity** 

(Yamaoka et al., 2000).

**4.3 Zinc in cell signaling** 

regulate intracellular zinc concentrations (Langmade et al., 2000). Other zinc finger transcription factors such as Egr-1, AP-1 and NF-B are important for the regulation of genes that control cells proliferation. Deregulation of these transcription factors contributes to cancer cells proliferation, metastasis and angiogenesis. How zinc affects the regulation of these transcription factors and their outcomes, however, varies. It is shown in a number of studies, that zinc at different concentrations activate or suppress the activities of NF-B in different cell lines resulting in different cellular responses (Kim et al., 2007; Uzzo et al., 2006; Uzzo et al., 2002).

Zinc modulates kinases and phosphatases of major cells signaling pathways. A number of studies showed that zinc stimulates EGF receptor phosphorylation and activates members of the MAPKs family such as ERK (Hansson, 1996; Klein et al., 2006; Samet et al., 1998; Uzzo et al., 2006) and p38 kinase (Huang et al., 1999; Wu et al., 1999; Wu et al., 2005) activities in prostate cancer cells, murine fibroblasts, human bronchial epithelial cells, human airway epithelial cells and mouse cortical cells. Zinc also induces the phosphorylation of p70S6 kinase in murine fibroblasts, c-jun N-terminal kinase (JNK) in mouse cortical cells through phosphatidylinositol 3-kinase (P13K) signaling pathway (Eom et al., 2001; Kim et al., 2000), protein kinase C (PKC) activation (Csermely et al., 1988), protein kinase B (PKB) and glycogen synthase kinase (GSK)-3 activities in neuroblastoma cells (An et al., 2005). A number of studies also described the role of zinc in the modulation of phosphatases. Treatment of the human airway epithelial cells and C6 rat glioma cells with zinc increased protein tyrosine phosphorylation by inhibiting phosphatases such as PTP1B and SHP-1 (Haase & Maret, 2005) and zinc also inhibits the dual-specificity phosphatase VHR (Kim et al., 2000). These findings illustrate the extensive involvement of zinc on cellular signaling pathways and genes transcription. Balanced zinc homeostasis, therefore is vital for normal cell growth and differentiation; and deviations from optimal zinc levels may contribute to pathophysiologic consequences observed in many zinc-related diseases. Most of these zincaffected pathways are also deregulated in many types of cancer and this further highlights the importance of zinc homeostasis in oncogenesis.

## **5. Zinc and the prostate gland**

The human prostate gland is divided into three distinct morphological regions which include the peripheral, central and transition zones (McNeal, 1981). The peripheral zone contains the majority of the glandular tissues present in the normal prostate and accounts for 70% of the volume in the young adult prostate. The central zone consists of larger acini and has a more complex ductal branching while the transition zone comprises of glands lobules with shorter ducts in comparison to those in the peripheral zone. The central and transition zones account for 25% and 5% of the prostate volume, respectively.

The normal peripheral zone of the prostate gland accumulates the highest concentrations of zinc in comparison to other soft tissues of the body (Kar & Chowdhury, 1966; Lahtonen, 1985). The ability to accumulate zinc in the peripheral zone is due to the presence of highly specialized secretory epithelial cells that is not found in the central zone of the prostate. hZIP1 transporter is an important transporter for uptake from the circulation and accumulation in the prostate gland (Costello et al., 1999; Desouki et al., 2007) while hZIP-2 and hZIP-3 retain zinc in the cellular compartment (Desouki et al., 2007).

hZIP1 transporters are downregulated in adenocarcinoma cells and in prostate intraepithelial neoplastic loci (PIN) (Rishi et al., 2003). This causes not only a decrease in zinc

Zinc Supplementation and Prostate Cancer 429

required in this area, these reports nevertheless, raised concern for potential detrimental

The beneficial effects of zinc in prostate cancer intervention and treatment were investigated *in vitro* and *in vivo* but yielded contradictory observations as well. Several *in vitro* zinc studies showed that zinc inhibits prostate cancer cells proliferation and invasion through the induction of necrotic cell death and caspase-mediated mitochondrial apoptogenesis (Feng et al., 2002; Feng et al., 2000; Iguchi et al., 1998; Liang et al., 1999). Other suggested inhibitory mechanisms include increased levels of Bax or decreased Bcl-2 and survivin expressionmediated apoptosis effect (Ku et al., 2010) and zinc-induced proteasomal degradation of HIF-1α, a protein often upregulated in tumors leading to more aggressive tumor growth and chemoresistance (Nardinocchi et al., 2010). In addition, zinc was reported to repress the metastatic potential of prostate cancer cells through various mechanisms. These include inhibition of NF-B activities (Uzzo et al., 2006), suppression of the invasive potentials of human prostate aminopeptidase N and urokinase-type plasminogen activator (Ishii et al., 2001a; Ishii et al., 2001b) as well as inhibiting proteolytic activities of prostate specific antigen (PSA) (Ishii et al., 2004). In contrast, it is also reported that zinc promotes cancer cell growth by enhancing telomerase activity, an enzyme thought to be responsible for the continuous proliferation of tumor cells (Nemoto et al., 2000) and suppressing the inhibitory potential of bisphosphonates on tumor cell invasion (Boissier et al., 2000). Our studies also showed that restoration of high zinc for a prolonged period could only inhibit zinc proliferation transiently, after which the malignant cell growth was restored and acquired a

more aggressive behaviour (Wong & Abubakar, 2008a; Wong & Abubakar, 2010).

higher levels it may enhance tumor growth (Prasad et al., 2010).

The association of zinc with prostate cancer and the therapeutic potentials of zinc in prostate cancer were also investigated *in vivo* (Table 1). Two early studies using xenograft mice inoculated with PC-3 cells (Feng et al., 2003) and PC-3-hZIP1 cells (Golovine et al., 2008) showed that zinc treatment resulted in inhibition of tumor growth. Feng et al. (2003) showed that inhibition of tumor growth was due to zinc-induced apoptosis. Golovine et al. (2008) showed that overexpression of hZIP1 transporter in PC3 cancer cells resulted in increased zinc uptake, decreased tumor volume and inhibition of NFB activity which are usually high in PC3 cells at physiological zinc serum range (0.5–1.5 μg/ml). Direct intratumoral injection of zinc in mM range was also shown to halt prostate cancer cell growth in xenograft mice (Shah et al., 2009) but the practicality of using intratumoral administration in human remains in question. Prasad et al. (2010) used a more relevant mouse model i.e. transgenic adenocarcinoma of the mouse prostate (TRAMP) mice in their study to determine the role of zinc in the development of prostate cancer. TRAMP mice develop spontaneous autochtonous disease which enables studies on the transformation of normal prostatic cells, progression and metastasis of prostate cancer (Gingrich et al., 1996). These mice were given 0.85 ppm zinc (deficient), 30 ppm zinc (optimal) and 150 ppm zinc (high) for 14 weeks. Their results showed that prostate tumor weights were higher at both zinc-deficient and high zinc-supplemented mice which led them to suggest that zinc at optimal levels is preventive whereas at both deficient and

outcomes of long-term use of high zinc-supplements in men.

**5.1.2** *In vitro* **studies** 

**5.1.3** *In vivo* **studies** 

uptake (Franklin et al., 2005a; Franklin et al., 2003; Franklin et al., 2005b) but also reduces the capacity to accumulate zinc (Huang et al., 2006). The downregulation of hZIP1 is also associated with high prostate cancer risk in African American male population in comparison with Caucasians (Rishi et al., 2003). hZIP2, hZIP3 and ZnT4 are also found downregulated in malignant tissues in comparison to nonmalignant and Benign prostatic hyperplasia (BPH) tissues (Beck et al., 2004; Desouki et al., 2007). These findings collectively suggest that alterations of intracellular zinc due to changes in zinc transporters expression are associated to the development prostate cancer. It is suggested that human *ZIP1*, *ZIP2* and *ZIP3* genes may be tumor suppressor genes (Desouki et al., 2007) and zinc may be a tumor suppressor agent (Franklin & Costello, 2007).

#### **5.1 Association of zinc with prostate cancer**

It is still unclear of the role of zinc in malignant diseases but abnormal levels of zinc in serum of cancer patients and malignant tissues are widely reported. Serum zinc levels are increased in melanoma patients (Ros-Bullon et al., 1998) but more often, reduced serum zinc levels are reported in breast (Sharma et al., 1994; Yucel et al., 1994), gallbladder (Gupta et al., 2005), lung (Diez et al., 1989; Issell et al., 1981), Hodgkin's disease (Cunzhi et al., 2001), colorectal (Gupta et al., 1993), neck (Buntzel et al., 2007), leukemia (Zuo et al., 2006) and thyroid (Al-Sayer et al., 2004) cancer patients. Elevated zinc levels in malignant tissues are observed in breast (Margalioth et al., 1983), intestinal (Kucharzewski et al., 2003), metastatic nasopharyngeal (Bay et al., 1997) cancers but are decreased in kidney carcinoma tissues (Margalioth et al., 1983). It is also high in bone marrow of patients with non-Hodgkin lymphomas (Schmitt et al., 1993). In prostate cancer, decreased zinc levels are consistently observed in malignant tissue samples from different populations and at various stages of malignancy (Vartsky et al., 2003; Zaichick et al., 1997). Analysis of malignant prostate tissues showed a 60-70% reduction of zinc levels in comparison to those of the normal peripheral zone tissues (Zaichick et al., 1997). The plasma zinc level between patients with malignancy is also significantly lower than normal patients (Goel & Sankhwar, 2006).

#### **5.1.1 Epidemiologic studies**

It is reported that dietary zinc supplementation protects against oxidative damage, reduces cancer risk (Ho, 2004) and is beneficial against prostate tumorigenesis (Franklin & Costello, 2007). Findings from several epidemiologic studies, however, attain no consensus on the effectiveness of zinc against prostate cancer, partly because of differences in experimental design, amount of zinc administered and methods in determining plasma/serum zinc status (Haase et al., 2008). Several studies showed that there are either no beneficiary effects of zinc or there are no potential adverse effects of dietary zinc on prostate cancer risk (Andersson et al., 1996; Kolonel, 1996; Vlajinac et al., 1997; West et al., 1991). In contrast, there are reports which concluded that zinc reduces prostate cancer risk (Epstein et al., 2011; Key et al., 1997; Kristal et al., 1999). Gonzalez et al. (2009) reported that dietary zinc was not associated with prostate cancer and 10-year average intake of supplemental zinc does not reduce the overall risk of prostate cancer. However, they found that risk of advanced prostate cancer decreases with greater intake of supplemental zinc in their VITamins And Lifestyle (VITAL) cohort study (Gonzalez et al., 2009). There are also reports that showed high zinc intake increases the risk of advanced prostate cancer (Gallus et al., 2007; Lawson et al., 2007; Leitzmann et al., 2003) and higher intake of dietary zinc could also potentiate the development of BPH and progression towards cancer (Lagiou et al., 1999; Moyad, 2004). Although further studies are required in this area, these reports nevertheless, raised concern for potential detrimental outcomes of long-term use of high zinc-supplements in men.

#### **5.1.2** *In vitro* **studies**

428 Prostate Cancer – From Bench to Bedside

uptake (Franklin et al., 2005a; Franklin et al., 2003; Franklin et al., 2005b) but also reduces the capacity to accumulate zinc (Huang et al., 2006). The downregulation of hZIP1 is also associated with high prostate cancer risk in African American male population in comparison with Caucasians (Rishi et al., 2003). hZIP2, hZIP3 and ZnT4 are also found downregulated in malignant tissues in comparison to nonmalignant and Benign prostatic hyperplasia (BPH) tissues (Beck et al., 2004; Desouki et al., 2007). These findings collectively suggest that alterations of intracellular zinc due to changes in zinc transporters expression are associated to the development prostate cancer. It is suggested that human *ZIP1*, *ZIP2* and *ZIP3* genes may be tumor suppressor genes (Desouki et al., 2007) and zinc may be a

It is still unclear of the role of zinc in malignant diseases but abnormal levels of zinc in serum of cancer patients and malignant tissues are widely reported. Serum zinc levels are increased in melanoma patients (Ros-Bullon et al., 1998) but more often, reduced serum zinc levels are reported in breast (Sharma et al., 1994; Yucel et al., 1994), gallbladder (Gupta et al., 2005), lung (Diez et al., 1989; Issell et al., 1981), Hodgkin's disease (Cunzhi et al., 2001), colorectal (Gupta et al., 1993), neck (Buntzel et al., 2007), leukemia (Zuo et al., 2006) and thyroid (Al-Sayer et al., 2004) cancer patients. Elevated zinc levels in malignant tissues are observed in breast (Margalioth et al., 1983), intestinal (Kucharzewski et al., 2003), metastatic nasopharyngeal (Bay et al., 1997) cancers but are decreased in kidney carcinoma tissues (Margalioth et al., 1983). It is also high in bone marrow of patients with non-Hodgkin lymphomas (Schmitt et al., 1993). In prostate cancer, decreased zinc levels are consistently observed in malignant tissue samples from different populations and at various stages of malignancy (Vartsky et al., 2003; Zaichick et al., 1997). Analysis of malignant prostate tissues showed a 60-70% reduction of zinc levels in comparison to those of the normal peripheral zone tissues (Zaichick et al., 1997). The plasma zinc level between patients with malignancy

It is reported that dietary zinc supplementation protects against oxidative damage, reduces cancer risk (Ho, 2004) and is beneficial against prostate tumorigenesis (Franklin & Costello, 2007). Findings from several epidemiologic studies, however, attain no consensus on the effectiveness of zinc against prostate cancer, partly because of differences in experimental design, amount of zinc administered and methods in determining plasma/serum zinc status (Haase et al., 2008). Several studies showed that there are either no beneficiary effects of zinc or there are no potential adverse effects of dietary zinc on prostate cancer risk (Andersson et al., 1996; Kolonel, 1996; Vlajinac et al., 1997; West et al., 1991). In contrast, there are reports which concluded that zinc reduces prostate cancer risk (Epstein et al., 2011; Key et al., 1997; Kristal et al., 1999). Gonzalez et al. (2009) reported that dietary zinc was not associated with prostate cancer and 10-year average intake of supplemental zinc does not reduce the overall risk of prostate cancer. However, they found that risk of advanced prostate cancer decreases with greater intake of supplemental zinc in their VITamins And Lifestyle (VITAL) cohort study (Gonzalez et al., 2009). There are also reports that showed high zinc intake increases the risk of advanced prostate cancer (Gallus et al., 2007; Lawson et al., 2007; Leitzmann et al., 2003) and higher intake of dietary zinc could also potentiate the development of BPH and progression towards cancer (Lagiou et al., 1999; Moyad, 2004). Although further studies are

is also significantly lower than normal patients (Goel & Sankhwar, 2006).

tumor suppressor agent (Franklin & Costello, 2007).

**5.1 Association of zinc with prostate cancer** 

**5.1.1 Epidemiologic studies** 

The beneficial effects of zinc in prostate cancer intervention and treatment were investigated *in vitro* and *in vivo* but yielded contradictory observations as well. Several *in vitro* zinc studies showed that zinc inhibits prostate cancer cells proliferation and invasion through the induction of necrotic cell death and caspase-mediated mitochondrial apoptogenesis (Feng et al., 2002; Feng et al., 2000; Iguchi et al., 1998; Liang et al., 1999). Other suggested inhibitory mechanisms include increased levels of Bax or decreased Bcl-2 and survivin expressionmediated apoptosis effect (Ku et al., 2010) and zinc-induced proteasomal degradation of HIF-1α, a protein often upregulated in tumors leading to more aggressive tumor growth and chemoresistance (Nardinocchi et al., 2010). In addition, zinc was reported to repress the metastatic potential of prostate cancer cells through various mechanisms. These include inhibition of NF-B activities (Uzzo et al., 2006), suppression of the invasive potentials of human prostate aminopeptidase N and urokinase-type plasminogen activator (Ishii et al., 2001a; Ishii et al., 2001b) as well as inhibiting proteolytic activities of prostate specific antigen (PSA) (Ishii et al., 2004). In contrast, it is also reported that zinc promotes cancer cell growth by enhancing telomerase activity, an enzyme thought to be responsible for the continuous proliferation of tumor cells (Nemoto et al., 2000) and suppressing the inhibitory potential of bisphosphonates on tumor cell invasion (Boissier et al., 2000). Our studies also showed that restoration of high zinc for a prolonged period could only inhibit zinc proliferation transiently, after which the malignant cell growth was restored and acquired a more aggressive behaviour (Wong & Abubakar, 2008a; Wong & Abubakar, 2010).

#### **5.1.3** *In vivo* **studies**

The association of zinc with prostate cancer and the therapeutic potentials of zinc in prostate cancer were also investigated *in vivo* (Table 1). Two early studies using xenograft mice inoculated with PC-3 cells (Feng et al., 2003) and PC-3-hZIP1 cells (Golovine et al., 2008) showed that zinc treatment resulted in inhibition of tumor growth. Feng et al. (2003) showed that inhibition of tumor growth was due to zinc-induced apoptosis. Golovine et al. (2008) showed that overexpression of hZIP1 transporter in PC3 cancer cells resulted in increased zinc uptake, decreased tumor volume and inhibition of NFB activity which are usually high in PC3 cells at physiological zinc serum range (0.5–1.5 μg/ml). Direct intratumoral injection of zinc in mM range was also shown to halt prostate cancer cell growth in xenograft mice (Shah et al., 2009) but the practicality of using intratumoral administration in human remains in question. Prasad et al. (2010) used a more relevant mouse model i.e. transgenic adenocarcinoma of the mouse prostate (TRAMP) mice in their study to determine the role of zinc in the development of prostate cancer. TRAMP mice develop spontaneous autochtonous disease which enables studies on the transformation of normal prostatic cells, progression and metastasis of prostate cancer (Gingrich et al., 1996). These mice were given 0.85 ppm zinc (deficient), 30 ppm zinc (optimal) and 150 ppm zinc (high) for 14 weeks. Their results showed that prostate tumor weights were higher at both zinc-deficient and high zinc-supplemented mice which led them to suggest that zinc at optimal levels is preventive whereas at both deficient and higher levels it may enhance tumor growth (Prasad et al., 2010).

Zinc Supplementation and Prostate Cancer 431

acetate + testosterone propionate fed with zinc sulfate heptahydrate dissolved in drinking water (227 mg/L or 227 ppm) for 20 weeks, they found high dietary zinc increased intraprostatic zinc concentrations and promoted prostate intraepithelial neoplasm (Ko et al., 2010). A much higher zinc and longer duration of treatment may be responsible for the observations made by Ko et al. (2010), it nevertheless suggests that high zinc treatment for a

It is established that zinc deficiency is associated with prostate cancer development based on the observation of significantly low/absence of zinc in cancerous prostate tissues and indirect evidences from *in vitro* and animal studies. It remains to be unraveled whether the absence of zinc is a consequence of cells transformation or whether zinc deficiency directly

A number of studies showed that zinc exerts both growth and metabolic effects on prostate cells and contribute to the development of prostate malignancy by altering citrate metabolism (Costello et al., 2004; Singh et al., 2006). It is reported in these studies that zinc inhibits *in vitro* cultured human prostate cell lines (LNCaP, PC3 and BPH-1) and rat ventral prostate epithelium cells proliferation by inducing mitochondrial apoptogenesis by releasing cytochrome *c*, which then activates subsequent caspase mediated-apoptotic cascading events leading to apoptosis. It is also shown that zinc inhibits the gene expression and activity of m-aconitase in prostate cells (Costello et al., 1997; Tsui et al., 2006). These findings led to the proposal that the presence of high zinc in normal prostate limits citrate oxidation via the Krebs cycle resulting in accumulation of high citrate levels for the secretion of prostatic fluids (Costello et al., 1997). In the transformed prostate cells, where zinc concentration is very low or absent, citrate oxidation can proceed via the Krebs cycle to generate ATP, thus, providing unlimited energy for malignant cells growth (Costello et al., 2004; Costello & Franklin, 2006). Concurrently, as intracellular zinc decreases, the apoptogenic effects of zinc are also removed, hence encourages malignant cells proliferation (Costello et al., 2004). Based on these observations, these authors suggest that restoration of

Although the proposed mechanisms are plausible, it is also discussed above that zinc has diverse effects on cellular processes and mediates various signaling transduction pathways including those that are implicated in the development and progression of prostate cancer. This point was exemplified in another study that showed the involvement of zinc in Akt pathway (Han et al., 2009). Akt/protein kinase B (PKB) gene is amplified in cancerous prostate tissues and increase in its kinase activities are associated with hormone-resistant prostate cancer (Edwards et al., 2003). Activation of Akt pathway promotes the survival and protection of cancer cells from apoptosis by inhibiting downstream death proteins such as Bad, caspase-9 and forkhead transcription factors (FHTF) (Cantley, 2002). Phosphatase and TENsin homolog (PTEN), a tumor suppressor, negatively regulate the phosphorylation of Akt and maintains it at basal level. Normal prostate cells accumulates high zinc and during zinc deficiency, Han et al. (2009) showed that Akt is hyperphosphorylated in prostate normal epithelial cells (PrEC) and led to Mdm2 phosphorylation and decreased nuclear accumulation of p53. This resulted in reduced tumor-suppressive effect of p53, hence, maintaining the progression of the cell cycle and promoting cell survival through an Akt-Mdm2-p53 signaling axis. In LNCaP prostate cancer cells where PTEN is deleted and mutated, Akt phosphorylation becomes

prolonged period may have detrimental outcomes.

contributes to transformation.

**5.2 Mechanisms of zinc-induced prostate cancer pathogenesis** 

zinc to prostate may be an effective treatment for prostate cancer.


Table 1. *In vivo* zinc studies using murine models

To investigate the chemopreventive potential of zinc, Banudevi et al. (2011) treated prostate cancer induced Sprague-Dawley rats using N-methyl-N-nitrosourea MNU+ testosterone (MNU + T) with zinc (100 ppm) thrice a week. The zinc-treated mice showed fewer incidences of hyperplasia, dysplasia, and prostatic intraepithelial neoplasia in the ventral prostate compared to the non-treated group (Banudevi et al., 2011). They concluded that zinc may act as a potential chemopreventive agent in targeting prostate cancer. However, in another study on prostate cancer induced Sprague-Dawley rats using MNU+ cyproterone

treatment Findings References

Feng et al., 2003

Golovine et al., 2008

Shah et al., 2009

Prasad et al.,

Banudevi et al., 2011

Ko et al., 2010

2010

Inhibition of tumor

Decreased tumor

Halted prostate cancer

tumor weights in zincdeficient or high-zinc

hyperplasia, dysplasia,

neoplasia in the ventral prostate zinc-treated

prostate intraepithelial

and prostatic intraepithelial

mice

20 weeks Increased incidence of

neoplasm

growth

volume

cells growth

14 weeks Significantly higher

100 ppm 3 times / week Fewer incidences of

To investigate the chemopreventive potential of zinc, Banudevi et al. (2011) treated prostate cancer induced Sprague-Dawley rats using N-methyl-N-nitrosourea MNU+ testosterone (MNU + T) with zinc (100 ppm) thrice a week. The zinc-treated mice showed fewer incidences of hyperplasia, dysplasia, and prostatic intraepithelial neoplasia in the ventral prostate compared to the non-treated group (Banudevi et al., 2011). They concluded that zinc may act as a potential chemopreventive agent in targeting prostate cancer. However, in another study on prostate cancer induced Sprague-Dawley rats using MNU+ cyproterone

fed mice

Duration of

(4 weeks)

(3.3 weeks)

direct intratumoral injection every 48 hours for a period of two weeks

Animal models

C.B17/ICR-SCID mice inoculated with PC-3-hZIP1 in the flank region

Nude mice inoculated with

NOD/SCID inoculated with PC3 cells in the dorsum of animals

Sprague-Dawley rats using Nmethyl-Nnitrosourea MNU+ testosterone (MNU + T)

Sprague-Dawley rats using MNU+ cyproterone acetate + testosterone propionate

PC3

Zinc concentrations given

200 μL of 3 mM zinc acetate per injection

(0.85 ppm), optimal (normal) zinc (30 ppm) and high zinc (150

ppm)

227 mg/L (equivalent to 227 ppm)

Table 1. *In vivo* zinc studies using murine models

TRAMP mice zinc deficient

0.25 µL/h 28 days

2000 ppm 23 days

acetate + testosterone propionate fed with zinc sulfate heptahydrate dissolved in drinking water (227 mg/L or 227 ppm) for 20 weeks, they found high dietary zinc increased intraprostatic zinc concentrations and promoted prostate intraepithelial neoplasm (Ko et al., 2010). A much higher zinc and longer duration of treatment may be responsible for the observations made by Ko et al. (2010), it nevertheless suggests that high zinc treatment for a prolonged period may have detrimental outcomes.

#### **5.2 Mechanisms of zinc-induced prostate cancer pathogenesis**

It is established that zinc deficiency is associated with prostate cancer development based on the observation of significantly low/absence of zinc in cancerous prostate tissues and indirect evidences from *in vitro* and animal studies. It remains to be unraveled whether the absence of zinc is a consequence of cells transformation or whether zinc deficiency directly contributes to transformation.

A number of studies showed that zinc exerts both growth and metabolic effects on prostate cells and contribute to the development of prostate malignancy by altering citrate metabolism (Costello et al., 2004; Singh et al., 2006). It is reported in these studies that zinc inhibits *in vitro* cultured human prostate cell lines (LNCaP, PC3 and BPH-1) and rat ventral prostate epithelium cells proliferation by inducing mitochondrial apoptogenesis by releasing cytochrome *c*, which then activates subsequent caspase mediated-apoptotic cascading events leading to apoptosis. It is also shown that zinc inhibits the gene expression and activity of m-aconitase in prostate cells (Costello et al., 1997; Tsui et al., 2006). These findings led to the proposal that the presence of high zinc in normal prostate limits citrate oxidation via the Krebs cycle resulting in accumulation of high citrate levels for the secretion of prostatic fluids (Costello et al., 1997). In the transformed prostate cells, where zinc concentration is very low or absent, citrate oxidation can proceed via the Krebs cycle to generate ATP, thus, providing unlimited energy for malignant cells growth (Costello et al., 2004; Costello & Franklin, 2006). Concurrently, as intracellular zinc decreases, the apoptogenic effects of zinc are also removed, hence encourages malignant cells proliferation (Costello et al., 2004). Based on these observations, these authors suggest that restoration of zinc to prostate may be an effective treatment for prostate cancer.

Although the proposed mechanisms are plausible, it is also discussed above that zinc has diverse effects on cellular processes and mediates various signaling transduction pathways including those that are implicated in the development and progression of prostate cancer. This point was exemplified in another study that showed the involvement of zinc in Akt pathway (Han et al., 2009). Akt/protein kinase B (PKB) gene is amplified in cancerous prostate tissues and increase in its kinase activities are associated with hormone-resistant prostate cancer (Edwards et al., 2003). Activation of Akt pathway promotes the survival and protection of cancer cells from apoptosis by inhibiting downstream death proteins such as Bad, caspase-9 and forkhead transcription factors (FHTF) (Cantley, 2002). Phosphatase and TENsin homolog (PTEN), a tumor suppressor, negatively regulate the phosphorylation of Akt and maintains it at basal level. Normal prostate cells accumulates high zinc and during zinc deficiency, Han et al. (2009) showed that Akt is hyperphosphorylated in prostate normal epithelial cells (PrEC) and led to Mdm2 phosphorylation and decreased nuclear accumulation of p53. This resulted in reduced tumor-suppressive effect of p53, hence, maintaining the progression of the cell cycle and promoting cell survival through an Akt-Mdm2-p53 signaling axis. In LNCaP prostate cancer cells where PTEN is deleted and mutated, Akt phosphorylation becomes

Zinc Supplementation and Prostate Cancer 433

their study, Fos, which codes for a transcription factor associated with AP-1, was dramatically up-regulated by short-term zinc treatment in PC-3 cells and up-regulation of c-Fos protein is known to occur in advanced human prostate cancer (Ouyang et al., 2008). They also showed that expression of the Akt1 and PIK3 genes, associated with the Akt pathway, was dramatically upregulated in normal cells but remained unaffected in the cancer cells. However, the long-term effect of zinc on the expression of these genes is not known since cells were only treated for 6 hours in this study. This observation nevertheless supports the role of zinc in regulating malignancy promoting genes in normal cells but its control is lost in the cancerous tissues. The consequences following the loss of zinc

Despite the contrasting reports on the effects of zinc on prostate cancer cells, these studies collectively affirmed the importance of zinc in the regulation of prostate health under normal physiologic conditions. Adverse consequences are apparent with zinc deficiency as well as with high zinc supplementation. The diverse effects of zinc on prostate cells reflects the immensity of zinc interactions with various cellular kinases, phosphatases, signaling transduction molecules and transcription factors in the regulation of normal cellular processes and immune responses, thereby also affecting those of the tumor cells and tumor microenvironment (John et al., 2010) once the normal cells transformed. Because of the extensive involvement of zinc in cellular signaling networks which includes its potential role in regulating cancer-promoting genes, simple restoration of high intracellular zinc concentration to the cancerous tissues may not be corrective. Instead, it may further fuel aberrant signaling in cancer cells leading to deleterious consequences. The use of zinc therapy based on its ability to induce apoptosis is effective perhaps when given intratumorally but dietary supplementation of zinc faces with issues of bioavailability and difficulties in achieving therapeutically meaningful dose in diseased prostate. The effects of chronic use of zinc still require further research with standardized zinc preparations, methods of zinc measurement, patient selection and statistical analysis to achieve a final consensus of the effectiveness of zinc in prostate cancer prevention and treatment. On the other hand, research focus on developing methods of using endogenous zinc (Ghosh et al., 2010) for early detection and progression of prostate cancer in human as well as utilizing zinc-regulated genes for diagnosis or targeting them for treatment of prostate cancer may be

The authors thank University of Malaya and Ministry of Science, Technology and Innovations, Malaysia for provision of research fundings received under Program of Research In Priority

Adamson, E., de Belle, I., Mittal, S., Wang, Y., Hayakawa, J., Korkmaz, K., O'Hagan, D.,

McClelland, M. & Mercola, D. (2003). Egr1 signaling in prostate cancer. *Cancer Biol Ther*, Vol. 2, No. 6. Nov-Dec, pp. 617-622, Issn 1538-4047 (Print) 1538-4047 (Linking)

Area (IRPA) Grant No. 06-02-03-1025, VotF-382/2005C and VotF-0173/2003B.

regulation of cancer-promoting genes warrant further research.

**6. Conclusion** 

more relevant in this regard.

**7. Acknowledgement** 

**8. References** 

uninhibited. In zinc-deficient LNCaP cells, it is suggested that Akt phosphorylates p21, inhibits its nuclear entry and promotes cytoplasmic degradation. Hence, zinc-deficient LNCaP cells could survive and progress through the G0/G1 phase of the cell cycle. This study showed that zinc is important in maintaining the survival of normal prostate cells and in its absence, the malignant cells uses alternative pathway to promote cell survival instead.

Difference in response to zinc between normal and malignant cells was also observed in our previous studies. We demonstrated an increasing percentage of senescent normal prostate PNT2 cells when treated with a high zinc concentration but this was not observed in LNCaP cells (Wong & Abubakar, 2008b). Hence, high zinc in the normal prostate regulates healthy prostate cell growth by maintaining senescence but this regulatory role is lost in zinc-deficient cancerous tissues. Han et al. (2009) also showed that cell growth was unchanged for LNCaP cells supplemented with high zinc although G2/M populations was depressed, which is similar to our observation (Wong & Abubakar, 2008a). Since there was no change in nuclear p21 level in high zinc-treated LNCaP cells in the study by Han et al., (2009), restoration of high zinc to LNCaP cells may have affected other pathways. We showed that restoration of high zinc to LNCaP for a longer period (5 weeks) resulted in upregulation of protein expression of Vaccinia H1-related (VHR) phosphatase, zeta chain-associated protein-70 (ZAP-70) kinase and phosphorylated extracellular signal-regulated protein kinase 1 and 2 (p-ERK 1 and 2) which declined after chelation of Zn2+, highlighting the possible association of zinc with VHR/ZAP-70-associated pathways in the modulation of LNCaP prostate cancer cell growth.

To further determine the effects of prolonged high zinc treatment on global gene expressions in LNCaP prostate cancer cells, we continuously cultured LNCaP cells for at least five passages over a 5 week period in growth medium supplemented with supraphysiologic concentrations of Zn2+ (Wong & Abubakar, 2010). Various methods were employed to demonstrate the intracellular accumulation of zinc and these are correlated with the cancer cell growth and proliferation. Specific gene expression analysis using microarray was used to examine the different gene expression levels and validated using quantitative real time polymerase chain reaction amplification. Using this approach it was observed that high intracellular zinc initially inhibited prostate cell growth and colony formation on soft agar. The inhibition, however, is transient as the cancer cell growth rate recovers to the pre-zinc treatment cancerous cell growth rate. Results from microarray studies using these prolonged high zinc-treated cells suggest that the recovery is accompanied by high expression of genes known to promote prostate cancer cell proliferation, migration and aggressiveness. Genes such as *FASN*, *FAD*, *TACSTD1*, *FBL*, *ADRM1*, *E2F3*, *CD164* and *STEAP1* are highly expressed. In addition, *CD164*, *FBL* and *TACSTD1* were also found upregulated in increasing presence of high zinc in normal prostate PNT2 cells. Collectively, these findings suggest that zinc initially suppresses cell growth, perhaps by repressing the expressions of selected growth promoting genes but the ability of zinc to regulate these genes in the cancerous tissues are eventually lost, resulting in the superinduction of the expression of these genes which in turn promote the survival of the prostate cancer cells even when the intracellular zinc level is high. These observations, thus, support the epidemiologic findings that high zinc intake is associated with the progression to advanced aggressive prostate cancer. In another gene profiling study of normal human prostatic cell line HPR-1 and androgen-independent malignant prostate cancer PC3 cells treated with zinc (20 M) for 1-6 hours, it was also observed that zinc affects many genes involved in oncogenesis pathways although genes associated with zinc accumulation and zinc-induced apoptosis are also found responsive (Lin et al., 2009). In

their study, Fos, which codes for a transcription factor associated with AP-1, was dramatically up-regulated by short-term zinc treatment in PC-3 cells and up-regulation of c-Fos protein is known to occur in advanced human prostate cancer (Ouyang et al., 2008). They also showed that expression of the Akt1 and PIK3 genes, associated with the Akt pathway, was dramatically upregulated in normal cells but remained unaffected in the cancer cells. However, the long-term effect of zinc on the expression of these genes is not known since cells were only treated for 6 hours in this study. This observation nevertheless supports the role of zinc in regulating malignancy promoting genes in normal cells but its control is lost in the cancerous tissues. The consequences following the loss of zinc regulation of cancer-promoting genes warrant further research.

## **6. Conclusion**

432 Prostate Cancer – From Bench to Bedside

uninhibited. In zinc-deficient LNCaP cells, it is suggested that Akt phosphorylates p21, inhibits its nuclear entry and promotes cytoplasmic degradation. Hence, zinc-deficient LNCaP cells could survive and progress through the G0/G1 phase of the cell cycle. This study showed that zinc is important in maintaining the survival of normal prostate cells and in its absence, the

Difference in response to zinc between normal and malignant cells was also observed in our previous studies. We demonstrated an increasing percentage of senescent normal prostate PNT2 cells when treated with a high zinc concentration but this was not observed in LNCaP cells (Wong & Abubakar, 2008b). Hence, high zinc in the normal prostate regulates healthy prostate cell growth by maintaining senescence but this regulatory role is lost in zinc-deficient cancerous tissues. Han et al. (2009) also showed that cell growth was unchanged for LNCaP cells supplemented with high zinc although G2/M populations was depressed, which is similar to our observation (Wong & Abubakar, 2008a). Since there was no change in nuclear p21 level in high zinc-treated LNCaP cells in the study by Han et al., (2009), restoration of high zinc to LNCaP cells may have affected other pathways. We showed that restoration of high zinc to LNCaP for a longer period (5 weeks) resulted in upregulation of protein expression of Vaccinia H1-related (VHR) phosphatase, zeta chain-associated protein-70 (ZAP-70) kinase and phosphorylated extracellular signal-regulated protein kinase 1 and 2 (p-ERK 1 and 2) which declined after chelation of Zn2+, highlighting the possible association of zinc with VHR/ZAP-

malignant cells uses alternative pathway to promote cell survival instead.

70-associated pathways in the modulation of LNCaP prostate cancer cell growth.

To further determine the effects of prolonged high zinc treatment on global gene expressions in LNCaP prostate cancer cells, we continuously cultured LNCaP cells for at least five passages over a 5 week period in growth medium supplemented with supraphysiologic concentrations of Zn2+ (Wong & Abubakar, 2010). Various methods were employed to demonstrate the intracellular accumulation of zinc and these are correlated with the cancer cell growth and proliferation. Specific gene expression analysis using microarray was used to examine the different gene expression levels and validated using quantitative real time polymerase chain reaction amplification. Using this approach it was observed that high intracellular zinc initially inhibited prostate cell growth and colony formation on soft agar. The inhibition, however, is transient as the cancer cell growth rate recovers to the pre-zinc treatment cancerous cell growth rate. Results from microarray studies using these prolonged high zinc-treated cells suggest that the recovery is accompanied by high expression of genes known to promote prostate cancer cell proliferation, migration and aggressiveness. Genes such as *FASN*, *FAD*, *TACSTD1*, *FBL*, *ADRM1*, *E2F3*, *CD164* and *STEAP1* are highly expressed. In addition, *CD164*, *FBL* and *TACSTD1* were also found upregulated in increasing presence of high zinc in normal prostate PNT2 cells. Collectively, these findings suggest that zinc initially suppresses cell growth, perhaps by repressing the expressions of selected growth promoting genes but the ability of zinc to regulate these genes in the cancerous tissues are eventually lost, resulting in the superinduction of the expression of these genes which in turn promote the survival of the prostate cancer cells even when the intracellular zinc level is high. These observations, thus, support the epidemiologic findings that high zinc intake is associated with the progression to advanced aggressive prostate cancer. In another gene profiling study of normal human prostatic cell line HPR-1 and androgen-independent malignant prostate cancer PC3 cells treated with zinc (20 M) for 1-6 hours, it was also observed that zinc affects many genes involved in oncogenesis pathways although genes associated with zinc accumulation and zinc-induced apoptosis are also found responsive (Lin et al., 2009). In Despite the contrasting reports on the effects of zinc on prostate cancer cells, these studies collectively affirmed the importance of zinc in the regulation of prostate health under normal physiologic conditions. Adverse consequences are apparent with zinc deficiency as well as with high zinc supplementation. The diverse effects of zinc on prostate cells reflects the immensity of zinc interactions with various cellular kinases, phosphatases, signaling transduction molecules and transcription factors in the regulation of normal cellular processes and immune responses, thereby also affecting those of the tumor cells and tumor microenvironment (John et al., 2010) once the normal cells transformed. Because of the extensive involvement of zinc in cellular signaling networks which includes its potential role in regulating cancer-promoting genes, simple restoration of high intracellular zinc concentration to the cancerous tissues may not be corrective. Instead, it may further fuel aberrant signaling in cancer cells leading to deleterious consequences. The use of zinc therapy based on its ability to induce apoptosis is effective perhaps when given intratumorally but dietary supplementation of zinc faces with issues of bioavailability and difficulties in achieving therapeutically meaningful dose in diseased prostate. The effects of chronic use of zinc still require further research with standardized zinc preparations, methods of zinc measurement, patient selection and statistical analysis to achieve a final consensus of the effectiveness of zinc in prostate cancer prevention and treatment. On the other hand, research focus on developing methods of using endogenous zinc (Ghosh et al., 2010) for early detection and progression of prostate cancer in human as well as utilizing zinc-regulated genes for diagnosis or targeting them for treatment of prostate cancer may be more relevant in this regard.

## **7. Acknowledgement**

The authors thank University of Malaya and Ministry of Science, Technology and Innovations, Malaysia for provision of research fundings received under Program of Research In Priority Area (IRPA) Grant No. 06-02-03-1025, VotF-382/2005C and VotF-0173/2003B.

## **8. References**

Adamson, E., de Belle, I., Mittal, S., Wang, Y., Hayakawa, J., Korkmaz, K., O'Hagan, D., McClelland, M. & Mercola, D. (2003). Egr1 signaling in prostate cancer. *Cancer Biol Ther*, Vol. 2, No. 6. Nov-Dec, pp. 617-622, Issn 1538-4047 (Print) 1538-4047 (Linking)

Zinc Supplementation and Prostate Cancer 435

Brown, M. A., Thom, J. V., Orth, G. L., Cova, P. & Juarez, J. (1964). Food poisoning involving

Buntzel, J., Bruns, F., Glatzel, M., Garayev, A., Mucke, R., Kisters, K., Schafer, U.,

Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. *Science*, Vol. 296, No. 5573. May 31, pp. 1655-1657, Issn 1095-9203 (Electronic) 0036-8075 (Linking) Coleman, J. E. (1992). Zinc proteins: Enzymes, storage proteins, transcription factors, and replication proteins. *Annu Rev Biochem*, Vol. 61, pp. 897-946, Issn 0066-4154 (Print) Costello, L. C., Feng, P., Milon, B., Tan, M. & Franklin, R. B. (2004). Role of zinc in the

*Cancer Prostatic Dis*, Vol. 7, No. 2. pp. 111-117, Issn 1365-7852 (Print) Costello, L. C. & Franklin, R. B. (1998). Novel role of zinc in the regulation of prostate citrate

pp. 285-296, Issn 0270-4137 (Print) 0270-4137 (Linking)

Issn 0250-7005 (Print) 0250-7005 (Linking)

pp. 17, Issn 1476-4598 (Electronic)

9258 (Print) 0021-9258 (Linking)

(Print) 0021-9258 (Linking)

(Print)

(Print)

zinc contamination. *Arch Environ Health*, Vol. 8, May, pp. 657-660, Issn 0003-9896

Schonekaes, K. & Micke, O. (2007). Zinc concentrations in serum during head and neck cancer progression. *Anticancer Res*, Vol. 27, No. 4A. Jul-Aug, pp. 1941-1943,

pathogenesis and treatment of prostate cancer: Critical issues to resolve. *Prostate* 

metabolism and its implications in prostate cancer. *Prostate*, Vol. 35, No. 4. Jun 1,

cancer; zinc and tumor suppression: Connecting the dots. *Mol Cancer*, Vol. 5, No.,

mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. *J Biol Chem*, Vol. 272, No. 46. Nov 14, pp. 28875-28881, Issn 0021-

in human prostate cancer cells which is regulated by prolactin and testosterone. *J* 

and signals. *J Biol Chem*, Vol. 281, No. 34. Aug 25, pp. 24085-24089, Issn 0021-9258

130, No. 5S Suppl. May, pp. 1384S-1387S, Issn 0022-3166 (Print) 0022-3166 (Linking)

protein kinase C and contributes to its binding to plasma membranes in T lymphocytes. *J Biol Chem*, Vol. 263, No. 14. May 15, pp. 6487-6490, Issn 0021-9258

prognostic value of serum copper/zinc ratio in Hodgkin's disease. *Biol Trace Elem* 

hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. *Mol Cancer*, Vol. 6, pp. 37, Issn 1476-4598 (Electronic) Deutsch, E., Maggiorella, L., Eschwege, P., Bourhis, J., Soria, J. C. & Abdulkarim, B. (2004).

Environmental, genetic, and molecular features of prostate cancer. *Lancet Oncol*,

Costello, L. C. & Franklin, R. B. (2006). The clinical relevance of the metabolism of prostate

Costello, L. C., Liu, Y., Franklin, R. B. & Kennedy, M. C. (1997). Zinc inhibition of

Costello, L. C., Liu, Y., Zou, J. & Franklin, R. B. (1999). Evidence for a zinc uptake transporter

*Biol Chem*, Vol. 274, No. 25. Jun 18, pp. 17499-17504, Issn 0021-9258 (Print) Cousins, R. J., Liuzzi, J. P. & Lichten, L. A. (2006). Mammalian zinc transport, trafficking,

Cousins, R. J. & McMahon, R. J. (2000). Integrative aspects of zinc transporters. *J Nutr*, Vol.

Csermely, P., Szamel, M., Resch, K. & Somogyi, J. (1988). Zinc can increase the activity of

Cunzhi, H., Jiexian, J., Xianwen, Z., Jingang, G. & Suling, H. (2001). Classification and

Desouki, M. M., Geradts, J., Milon, B., Franklin, R. B. & Costello, L. C. (2007). hZip2 and

Vol. 5, No. 5. May, pp. 303-313, Issn 1470-2045 (Print) 1470-2045 (Linking)

*Res*, Vol. 83, No. 2. Nov, pp. 133-138, Issn 0163-4984 (Print)


Al-Sayer, H., Mathew, T. C., Asfar, S., Khourshed, M., Al-Bader, A., Behbehani, A. & Dashti,

Andersson, S. O., Wolk, A., Bergstrom, R., Giovannucci, E., Lindgren, C., Baron, J. & Adami,

Banudevi, S., Elumalai, P., Arunkumar, R., Senthilkumar, K., Gunadharini, D. N., Sharmila,

Baum, M. K., Shor-Posner, G. & Campa, A. (2000). Zinc status in human immunodeficiency

Bay, B., Chan, Y., Fong, C. & Leong, H. (1997). Differential cellular zinc levels in metastatic

Beck, F. W., Prasad, A. S., Butler, C. E., Sakr, W. A., Kucuk, O. & Sarkar, F. H. (2004).

Berg, J. M. & Shi, Y. (1996). The galvanization of biology: A growing appreciation for the

Beyersmann, D. & Haase, H. (2001). Functions of zinc in signaling, proliferation and

Black, R. E. (2003). Zinc deficiency, infectious disease and mortality in the developing world.

Blakemore, L. J. & Trombley, P. Q. (2004). Diverse modulation of olfactory bulb AMPA

Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F. H., Colombel, M.,

Borovansky, J. (1994). Zinc in pigmented cells and structures, interactions and possible roles. *Sb Lek*, Vol. 95, No. 4. pp. 309-320, Issn 0036-5327 (Print) 0036-5327 (Linking) Brewer, G. J. (2001). Zinc acetate for the treatment of Wilson's disease. *Expert Opin Pharmacother*, Vol. 2, No. 9. Sep, pp. 1473-1477, Issn 1465-6566 (Print)

1115, Issn 0022-3042 (Print) 0022-3042 (Linking)

1432-1335 (Electronic) 0171-5216 (Linking)

Issn 1019-6439 (Print) 1019-6439 (Linking)

Mar 1, pp. 374-381, Issn 0270-4137 (Print)

Issn 0966-0844 (Print) 0966-0844 (Linking)

(Print) 0022-3166 (Linking)

(Print) 0036-8075 (Linking)

3166 (Linking)

0008-5472 (Linking)

(Print)

0020-7136 (Print)

H. (2004). Serum changes in trace elements during thyroid cancers. *Mol Cell Biochem*, Vol. 260, No. 1-2. May, pp. 1-5, Issn 0300-8177 (Print) 0300-8177 (Linking) An, W. L., Bjorkdahl, C., Liu, R., Cowburn, R. F., Winblad, B. & Pei, J. J. (2005). Mechanism

of zinc-induced phosphorylation of p70 s6 kinase and glycogen synthase kinase 3beta in sh-sy5y neuroblastoma cells. *J Neurochem*, Vol. 92, No. 5. Mar, pp. 1104-

H. O. (1996). Energy, nutrient intake and prostate cancer risk: A population-based case-control study in Sweden. *Int J Cancer*, Vol. 68, No. 6. Dec 11, pp. 716-722, Issn

G. & Arunakaran, J. (2011). Chemopreventive effects of zinc on prostate carcinogenesis induced by N-methyl-N-nitrosourea and testosterone in adult male sprague-dawley rats. *J Cancer Res Clin Oncol*, Vol. 137, No. 4. Apr, pp. 677-686, Issn

virus infection. *J Nutr*, Vol. 130, No. 5S Suppl. May, pp. 1421S-1423S, Issn 0022-3166

and primary nasopharyngeal carcinoma. *Int J Oncol*, Vol. 11, No. 4. Oct, pp. 745-748,

Differential expression of hZnT-4 in human prostate tissues. *Prostate*, Vol. 58, No. 4.

roles of zinc. *Science*, Vol. 271, No. 5252. Feb 23, pp. 1081-1085, Issn 0036-8075

differentiation of mammalian cells. *Biometals*, Vol. 14, No. 3-4. Sep-Dec, pp. 331-341,

*J Nutr*, Vol. 133, No. 5 Suppl 1. May, pp. 1485S-1489S, Issn 0022-3166 (Print) 0022-

receptors by zinc. *Neuroreport*, Vol. 15, No. 5. Apr 9, pp. 919-923, Issn 0959-4965

Delmas, P., Delaisse, J. M. & Clezardin, P. (2000). Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. *Cancer Res*, Vol. 60, No. 11. Jun 1, pp. 2949-2954, Issn 0008-5472 (Print)


Zinc Supplementation and Prostate Cancer 437

Franklin, R. B., Ma, J., Zou, J., Guan, Z., Kukoyi, B. I., Feng, P. & Costello, L. C. (2003).

Franklin, R. B., Milon, B., Feng, P. & Costello, L. C. (2005b). Zinc and zinc transporters in

Frederickson, C. J. (1989). Neurobiology of zinc and zinc-containing neurons. *Int Rev* 

Fukada, T., Yamasaki, S., Nishida, K., Murakami, M. & Hirano, T. (2011). Zinc homeostasis

Gallus, S., Foschi, R., Negri, E., Talamini, R., Franceschi, S., Montella, M., Ramazzotti, V.,

Ghosh, S. K., Kim, P., Zhang, X. A., Yun, S. H., Moore, A., Lippard, S. J. & Medarova, Z.

Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J.,

Giovannucci, E. (2001). Medical history and etiology of prostate cancer. *Epidemiol Rev*, Vol.

Goel, T. & Sankhwar, S. N. (2006). Comparative study of zinc levels in benign and malignant

Golovine, K., Makhov, P., Uzzo, R. G., Shaw, T., Kunkle, D. & Kolenko, V. M. (2008).

Gupta, S. K., Shukla, V. K., Vaidya, M. P., Roy, S. K. & Gupta, S. (1993). Serum and tissue

Gupta, S. K., Singh, S. P. & Shukla, V. K. (2005). Copper, zinc, and cu/zn ratio in carcinoma

Haase, H. & Maret, W. (2005). Protein tyrosine phosphatases as targets of the combined

23, No. 1. pp. 159-162, Issn 0193-936X (Print) 0193-936X (Linking)

(Print)

2230-2239, Issn 1093-4715 (Electronic)

Issn 0302-2838 (Print)

*Neurobiol*, Vol. 31, pp. 145-238, Issn 0074-7742 (Print)

pp., Issn 1432-1327 (Electronic) 0949-8257 (Linking)

1538-7445 (Electronic) 0008-5472 (Linking)

0008-5472 (Print) 0008-5472 (Linking)

5599 (Print) 0036-5599 (Linking)

(Electronic) 0163-5581 (Linking)

(Print) 0022-4790 (Linking)

Issn 0022-4790 (Print) 0022-4790 (Linking)

338, Issn 0966-0844 (Print) 0966-0844 (Linking)

Human Zip1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. *J Inorg Biochem*, Vol. 96, No. 2-3. Aug 1, pp. 435-442, Issn 0162-0134

normal prostate and the pathogenesis of prostate cancer. *Front Biosci*, Vol. 10, pp.

and signaling in health and diseases: Zinc signaling. *J Biol Inorg Chem*, Vol., Jun 10,

Tavani, A., Dal Maso, L. & La Vecchia, C. (2007). Dietary zinc and prostate cancer risk: A case-control study from Italy. *Eur Urol*, Vol. 52, No. 4. Oct, pp. 1052-1056,

(2010). A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. *Cancer Res*, Vol. 70, No. 15. Aug 1, pp. 6119-6127, Issn

Angelopoulou, R., Rosen, J. M. & Greenberg, N. M. (1996). Metastatic prostate cancer in a transgenic mouse. *Cancer Res*, Vol. 56, No. 18. Sep 15, pp. 4096-4102, Issn

lesions of the prostate. *Scand J Urol Nephrol*, Vol. 40, No. 2. pp. 108-112, Issn 0036-

Overexpression of the zinc uptake transporter hZip1 inhibits Nuclear FactorkappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. *Clin Cancer Res*, Vol. 14, No. 17. Sep 1, pp. 5376-5384, Issn 1078-0432 (Print) Gonzalez, A., Peters, U., Lampe, J. W. & White, E. (2009). Zinc intake from supplements and

diet and prostate cancer. *Nutr Cancer*, Vol. 61, No. 2. pp. 206-215, Issn 1532-7914

trace elements in colorectal cancer. *J Surg Oncol*, Vol. 52, No. 3. Mar, pp. 172-175,

of the gallbladder. *J Surg Oncol*, Vol. 91, No. 3. Sep 1, pp. 204-208, Issn 0022-4790

insulinomimetic effects of zinc and oxidants. *Biometals*, Vol. 18, No. 4. Aug, pp. 333-


Diez, M., Arroyo, M., Cerdan, F. J., Munoz, M., Martin, M. A. & Balibrea, J. L. (1989). Serum

Edwards, J., Krishna, N. S., Witton, C. J. & Bartlett, J. M. (2003). Gene amplifications

Eide, D. J. (2004). The slc39 family of metal ion transporters. *Pflugers Arch*, Vol. 447, No. 5.

Eom, S. J., Kim, E. Y., Lee, J. E., Kang, H. J., Shim, J., Kim, S. U., Gwag, B. J. & Choi, E. J.

Epstein, M. M., Kasperzyk, J. L., Andren, O., Giovannucci, E. L., Wolk, A., Hakansson, N.,

Feng, P., Li, T. L., Guan, Z. X., Franklin, R. B. & Costello, L. C. (2002). Direct effect of zinc on

Feng, P., Li, T. L., Guan, Z. X., Franklin, R. B. & Costello, L. C. (2003). Effect of zinc on

Feng, P., Liang, J. Y., Li, T. L., Guan, Z. X., Zou, J., Franklin, R. & Costello, L. C. (2000). Zinc

Feustel, A. & Wennrich, R. (1984). Determination of the distribution of zinc and cadmium in

Fischer Walker, C. & Black, R. E. (2004). Zinc and the risk for infectious disease. *Annu Rev* 

Food and Nutrition Board, Institute of Medicine, National Academies. (2010a). Dietary

*Agriculture Library*, 24.06.2011, Available from: http://fnic.nal.usda.gov Food and Nutrition Board, Institute of Medicine, National Academies. (2010b). Dietary

Franklin, R. B. & Costello, L. C. (2007). Zinc as an anti-tumor agent in prostate cancer and in

Franklin, R. B., Feng, P., Milon, B., Desouki, M. M., Singh, K. K., Kajdacsy-Balla, A., Bagasra,

Feb, pp. 796-800, Issn 0031-6768 (Print) 0031-6768 (Linking)

pp. 586-593, Issn 1938-3207 (Electronic) 0002-9165 (Linking)

316-320, Issn 0077-8923 (Print) 0077-8923 (Linking)

Vol. 12, No. 5. pp. 253-256, Issn 0300-5623 (Print)

*Nutr*, Vol. 24, pp. 255-275, Issn 0199-9885 (Print)

Spring, pp. 31-36, Issn 1091-5362 (Print)

Issn 0030-2414 (Print) 0030-2414 (Linking)

Issn 0026-895X (Print) 0026-895X (Linking)

311-318, Issn 0270-4137 (Print)

http://fnic.nal.usda.gov

9861 (Print)

(Electronic)

and tissue trace metal levels in lung cancer. *Oncology*, Vol. 46, No. 4. pp. 230-234,

associated with the development of hormone-resistant prostate cancer. *Clin Cancer Res*, Vol. 9, No. 14. Nov 1, pp. 5271-5281, Issn 1078-0432 (Print) 1078-0432 (Linking)

(2001). Zn(2+) induces stimulation of the c-jun n-terminal kinase signaling pathway through phosphoinositide 3-kinase. *Mol Pharmacol*, Vol. 59, No. 5. May, pp. 981-986,

Andersson, S. O., Johansson, J. E., Fall, K. & Mucci, L. A. (2011). Dietary zinc and prostate cancer survival in a swedish cohort. *Am J Clin Nutr*, Vol. 93, No. 3. Mar,

mitochondrial apoptogenesis in prostate cells. *Prostate*, Vol. 52, No. 4. Sep 1, pp.

prostatic tumorigenicity in nude mice. *Ann N Y Acad Sci*, Vol. 1010, No., Dec, pp.

induces mitochondria apoptogenesis in prostate cells. *Mol Urol*, Vol. 4, No. 1.

cellular fractions of BPH, normal prostate and prostatic cancers of different histologies by atomic and laser absorption spectrometry in tissue slices. *Urol Res*,

Reference Intakes (DRIs): Recommended Dietary Allowances and Adequate Intakes and Vitamins, In: *United States Department of Agriculture, National* 

Reference Intakes (DRIs): Tolerable Upper Intake Levels, Elements, In: *United States Department of Agriculture, National Agriculture Library*, 24.06.2011, Available from:

other cancers. *Arch Biochem Biophys*, Vol. 463, No. 2. Jul 15, pp. 211-217, Issn 0003-

O. & Costello, L. C. (2005a). Hzip1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. *Mol Cancer*, Vol. 4, pp. 32, Issn 1476-4598


Zinc Supplementation and Prostate Cancer 439

Issell, B. F., MacFadyen, B. V., Gum, E. T., Valdivieso, M., Dudrick, S. J. & Bodey, G. P.

Jemal, A., Siegel, R., Xu, J. & Ward, E. (2010). Cancer statistics, 2010. *CA Cancer J Clin*, Vol. 60, No. 5. Sep-Oct, pp. 277-300, Issn 1542-4863 (Electronic) 0007-9235 (Linking) John, E., Laskow, T. C., Buchser, W. J., Pitt, B. R., Basse, P. H., Butterfield, L. H., Kalinski, P.

Johnson, A. R., Munoz, A., Gottlieb, J. L. & Jarrard, D. F. (2007). High Dose Zinc Increases

Kadrmas, J. L. & Beckerle, M. C. (2004). The LIM domain: From the cytoskeleton to the

Kar, A. B. & Chowdhury, A. R. (1966). The distribution of zinc in the subcellular fractions of

Key, T. J., Silcocks, P. B., Davey, G. K., Appleby, P. N. & Bishop, D. T. (1997). A case-control

Kim, J. H., Cho, H., Ryu, S. E. & Choi, M. U. (2000). Effects of metal ions on the activity of

Kim, Y. M., Cao, D., Reed, W., Wu, W., Jaspers, I., Tal, T., Bromberg, P. A. & Samet, J. M.

Klein, C., Creach, K., Irintcheva, V., Hughes, K. J., Blackwell, P. L., Corbett, J. A. &

Ko, Y. H., Woo, Y. J., Kim, J. W., Choi, H., Kang, S. H., Lee, J. G., Kim, J. J., Park, H. S. &

Kolonel, L. N. (1996). Nutrition and prostate cancer. *Cancer Causes Control*, Vol. 7, No. 1. Jan,

Kristal, A. R., Stanford, J. L., Cohen, J. H., Wicklund, K. & Patterson, R. E. (1999). Vitamin

Issn 1745-7262 (Electronic) 1008-682X (Linking)

pp. 83-44, Issn 0957-5243 (Print) 0957-5243 (Linking)

1845-1848, Issn 0008-543X (Print) 0008-543X (Linking)

Vol. 8, pp. 118, Issn 1479-5876 (Electronic)

Feb 2007, pp. 639-643, ISSN 0022-5347 (Print)

0022-5347 (Print) 0022-5347 (Linking)

0920 (Print) 0007-0920 (Linking)

Issn 0003-9861 (Print)

Issn 0898-6568 (Print)

(Print) 1055-9965 (Linking)

9258 (Print)

(Print)

(1981). Serum zinc levels in lung cancer patients. *Cancer*, Vol. 47, No. 7. Apr 1, pp.

& Lotze, M. T. (2010). Zinc in innate and adaptive tumor immunity. *J Transl Med*,

Hospital Admissions Due To Genitourinary Complications. J Urol, Vol. 177, No. 2,

nucleus. *Nat Rev Mol Cell Biol*, Vol. 5, No. 11. Nov, pp. 920-931, Issn 1471-0072

the rhesus monkey and rat prostate. *J Urol*, Vol. 96, No. 3. Sep, pp. 370-371, Issn

study of diet and prostate cancer. *Br J Cancer*, Vol. 76, No. 5. pp. 678-687, Issn 0007-

protein tyrosine phosphatase VHR: Highly potent and reversible oxidative inactivation by Cu2+ ion. *Arch Biochem Biophys*, Vol. 382, No. 1. Oct 1, pp. 72-80,

(2007). Zn2+-induced NF-kappaB-dependent transcriptional activity involves sitespecific p65/RelA phosphorylation. *Cell Signal*, Vol. 19, No. 3. Mar, pp. 538-546,

Baldassare, J. J. (2006). Zinc induces ERK-dependent cell death through a specific ras isoform. *Apoptosis*, Vol. 11, No. 11. Nov, pp. 1933-1944, Issn 1360-8185 (Print) Klein, C., Sunahara, R. K., Hudson, T. Y., Heyduk, T. & Howlett, A. C. (2002). Zinc inhibition

of CAMP signaling. *J Biol Chem*, Vol. 277, No. 14. Apr 5, pp. 11859-11865, Issn 0021-

Cheon, J. (2010). High-dose dietary zinc promotes prostate intraepithelial neoplasia in a murine tumor induction model. *Asian J Androl*, Vol. 12, No. 2. Mar, pp. 164-170,

and mineral supplement use is associated with reduced risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*, Vol. 8, No. 10. Oct, pp. 887-892, Issn 1055-9965


Haase, H., Overbeck, S. & Rink, L. (2008). Zinc supplementation for the treatment or

Han, C. T., Schoene, N. W. & Lei, K. Y. (2009). Influence of zinc deficiency on Akt-Mdm2-

Hansson, A. (1996). Extracellular zinc ions induces mitogen-activated protein kinase activity

Herbein, G., Varin, A. & Fulop, T. (2006). NF-kappaB, AP-1, zinc-deficiency and aging. *Biogerontology*, Vol. 7, No. 5-6. Oct-Dec, pp. 409-419, Issn 1389-5729 (Print) Ho, E. (2004). Zinc deficiency, DNA damage and cancer risk. *J Nutr Biochem*, Vol. 15, No. 10.

Hu, H., Bandell, M., Petrus, M. J., Zhu, M. X. & Patapoutian, A. (2009). Zinc activates

Huang, L., Kirschke, C. P. & Zhang, Y. (2006). Decreased intracellular zinc in human

Iguchi, K., Hamatake, M., Ishida, R., Usami, Y., Adachi, T., Yamamoto, H., Koshida, K.,

Ishii, K., Otsuka, T., Iguchi, K., Usui, S., Yamamoto, H., Sugimura, Y., Yoshikawa, K.,

Ishii, K., Usui, S., Sugimura, Y., Yamamoto, H., Yoshikawa, K. & Hirano, K. (2001a).

*Lett*, Vol. 207, No. 1. Apr 15, pp. 79-87, Issn 0304-3835 (Print)

No. 5. May, pp. 394-408, Issn 0531-5565 (Print) 0531-5565 (Linking)

(Electronic) 0363-6143 (Linking)

717, Issn 0899-9007 (Print) 0899-9007 (Linking)

Issn 1552-4469 (Electronic) 1552-4450 (Linking)

Oct, pp. 572-578, Issn 0955-2863 (Print)

0898-6568 (Print)

0014-2956 (Linking)

0020-7136 (Print)

prevention of disease: Current status and future perspectives. *Exp Gerontol*, Vol. 43,

p53 and Akt-p21 signaling axes in normal and malignant human prostate cells. *Am J Physiol Cell Physiol*, Vol. 297, No. 5. Nov, pp. C1188-1199, Issn 1522-1563

and protein tyrosine phosphorylation in bombesin-sensitive swiss 3T3 fibroblasts. *Arch Biochem Biophys*, Vol. 328, No. 2. Apr 15, pp. 233-238, Issn 0003-9861 (Print) Hennig, B., Toborek, M. & McClain, C. J. (1996). Antiatherogenic properties of zinc:

Implications in endothelial cell metabolism. *Nutrition*, Vol. 12, No. 10. Oct, pp. 711-

damage-sensing TRPA1 ion channels. *Nat Chem Biol*, Vol. 5, No. 3. Mar, pp. 183-190,

tumorigenic prostate epithelial cells: A possible role in prostate cancer progression. *Cancer Cell Int*, Vol. 6, No., pp. 10, Issn 1475-2867 (Electronic) 1475-2867 (Linking) Huang, S., Maher, V. M. & McCormick, J. (1999). Involvement of intermediary metabolites in

the pathway of extracellular Ca2+-induced mitogen-activated protein kinase activation in human fibroblasts. *Cell Signal*, Vol. 11, No. 4. Apr, pp. 263-274, Issn

Uchibayashi, T. & Hirano, K. (1998). Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. *Eur J Biochem*, Vol. 253, No. 3. May 1, pp. 766-770, Issn 0014-2956 (Print)

Hayward, S. W. & Hirano, K. (2004). Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. *Cancer* 

Inhibition of Aminopeptidase N (AP-N) and Urokinase-type Plasminogen Activator (UPA) by zinc suppresses the invasion activity in human urological cancer cells. *Biol Pharm Bull*, Vol. 24, No. 3. Mar, pp. 226-230, Issn 0918-6158 (Print) Ishii, K., Usui, S., Sugimura, Y., Yoshida, S., Hioki, T., Tatematsu, M., Yamamoto, H. &

Hirano, K. (2001b). Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. *Int J Cancer*, Vol. 92, No. 1. Apr 1, pp. 49-54, Issn


Zinc Supplementation and Prostate Cancer 441

Moyad, M. A. (2004). Zinc for prostate disease and other conditions: A little evidence, a lot

Nardinocchi, L., Pantisano, V., Puca, R., Porru, M., Aiello, A., Grasselli, A., Leonetti, C.,

*Biochem Pharmacol*, Vol. 59, No. 4. Feb 15, pp. 401-405, Issn 0006-2952 (Print) Omu, A. E., Dashti, H. & Al-Othman, S. (1998). Treatment of asthenozoospermia with zinc

Osendarp, S. J., West, C. E. & Black, R. E. (2003). The need for maternal zinc

Ouyang, X., Jessen, W. J., Al-Ahmadie, H., Serio, A. M., Lin, Y., Shih, W. J., Reuter, V. E.,

Ozturk, A., Baltaci, A. K., Mogulkoc, R., Oztekin, E. & Kul, A. (2005). The effects of zinc

Parviz, M. & Gross, G. W. (2007). Quantification of zinc toxicity using neuronal networks on

Prasad, A. S. (1993). Zinc in human health and disease. *J Assoc Physicians India*, Vol. 41, No.

Prasad, A. S. (1998). Zinc and immunity. *Mol Cell Biochem*, Vol. 188, No. 1-2. Nov, pp. 63-69,

Prasad, A. S. (2008). Clinical, immunological, anti-inflammatory and antioxidant roles of

Prasad, A. S., Halsted, J. A. & Nadimi, M. (1961). Syndrome of iron deficiency anemia,

Prasad, A. S., Mantzoros, C. S., Beck, F. W., Hess, J. W. & Brewer, G. J. (1996). Zinc status

8. Aug, pp. 519-521, Issn 0004-5772 (Print) 0004-5772 (Linking)

No. 3. Mar, pp. 817S-827S, Issn 0022-3166 (Print) 0022-3166 (Linking) Outten, C. E. & O'Halloran, T. V. (2001). Femtomolar sensitivity of metalloregulatory

2492, Issn 0036-8075 (Print) 0036-8075 (Linking)

Oct, pp. 548-554, Issn 0172-780X (Print)

Issn 0300-8177 (Print) 0300-8177 (Linking)

Oct, pp. 532-546, Issn 0002-9343 (Print)

344-348, Issn 0899-9007 (Print) 0899-9007 (Linking)

813X (Print) 0161-813X (Linking)

2132-2144, Issn 1538-7445 (Electronic) 0008-5472 (Linking)

vivo. *PLoS ONE*, Vol. 5, No. 12. pp. e15048, Issn 1932-6203 (Electronic) Nemoto, K., Kondo, Y., Himeno, S., Suzuki, Y., Hara, S., Akimoto, M. & Imura, N. (2000).

52, Issn 1053-816X (Print)

(Linking)

(Linking)

of hype, and a significant potential problem. *Urol Nurs*, Vol. 24, No. 1. Feb, pp. 49-

Safran, M., Rechavi, G., Givol, D., Farsetti, A. & D'Orazi, G. (2010). Zinc downregulates HIF-1alpha and inhibits its activity in tumor cells in vitro and in

Modulation of telomerase activity by zinc in human prostatic and renal cancer cells.

sulphate: Andrological, immunological and obstetric outcome. *Eur J Obstet Gynecol Reprod Biol*, Vol. 79, No. 2. Aug, pp. 179-184, Issn 0301-2115 (Print) 0301-2115

supplementation in developing countries: An unresolved issue. *J Nutr*, Vol. 133,

proteins controlling zinc homeostasis. *Science*, Vol. 292, No. 5526. Jun 29, pp. 2488-

Scardino, P. T., Shen, M. M., Aronow, B. J., Vickers, A. J., Gerald, W. L. & Abate-Shen, C. (2008). Activator Protein-1 transcription factors are associated with progression and recurrence of prostate cancer. *Cancer Res*, Vol. 68, No. 7. Apr 1, pp.

deficiency and testosterone supplementation on leptin levels in castrated rats and their relation with LH, FSH and testosterone. *Neuro Endocrinol Lett*, Vol. 26, No. 5.

microelectrode arrays. *Neurotoxicology*, Vol. 28, No. 3. May, pp. 520-531, Issn 0161-

zinc. *Exp Gerontol*, Vol. 43, No. 5. May, pp. 370-377, Issn 0531-5565 (Print) 0531-5565

hepatosplenomegaly, hypogonadism, dwarfism and geophagia. *Am J Med*, Vol. 31,

and serum testosterone levels of healthy adults. *Nutrition*, Vol. 12, No. 5. May, pp.


Ku, J. H., Seo, S. Y., Kwak, C. & Kim, H. H. (2010). The role of survivin and bcl-2 in zinc-

Kucharzewski, M., Braziewicz, J., Majewska, U. & Gozdz, S. (2003). Selenium, copper, and

Lagiou, P., Wuu, J., Trichopoulou, A., Hsieh, C. C., Adami, H. O. & Trichopoulos, D. (1999).

Lahtonen, R. (1985). Zinc and cadmium concentrations in whole tissue and in separated

Lawson, K. A., Wright, M. E., Subar, A., Mouw, T., Hollenbeck, A., Schatzkin, A. &

Liang, J. Y., Liu, Y. Y., Zou, J., Franklin, R. B., Costello, L. C. & Feng, P. (1999). Inhibitory

Lin, S. F., Wei, H., Maeder, D., Franklin, R. B. & Feng, P. (2009). Profiling of zinc-altered gene

Magistretti, J., Castelli, L., Taglietti, V. & Tanzi, F. (2003). Dual effect of Zn2+ on multiple

Maret, W. & Sandstead, H. H. (2006). Zinc requirements and the risks and benefits of zinc

Margalioth, E. J., Schenker, J. G. & Chevion, M. (1983). Copper and zinc levels in normal and

Maverakis, E., Fung, M. A., Lynch, P. J., Draznin, M., Michael, D. J., Ruben, B. & Fazel, N.

McNeal, J. E. (1981). The zonal anatomy of the prostate. *Prostate*, Vol. 2, No. 1. pp. 35-49, Issn

*Neuroscience*, Vol. 117, No. 2. pp. 249-264, Issn 0306-4522 (Print)

Vol. 6, No. 2. pp. 177-183, Issn 0270-4137 (Print) 0270-4137 (Linking) Langmade, S. J., Ravindra, R., Daniels, P. J. & Andrews, G. K. (2000). The transcription factor

2496 (Electronic) 1078-1439 (Linking)

Aug, pp. 284-290, Issn 1527-9995 (Electronic)

44. Nov 3, pp. 34803-34809, Issn 0021-9258 (Print)

No. 13. Jul 2, pp. 1004-1007, Issn 1460-2105 (Electronic)

Aug 1, pp. 200-207, Issn 0270-4137 (Print)

(Linking)

(Linking)

(Linking)

(Print) 0946-672X (Linking)

0270-4137 (Print) 0270-4137 (Linking)

0008-543X (Linking)

induced apoptosis in prostate cancer cells. *Urol Oncol*, Vol., Sep 3, pp., Issn 1873-

zinc concentrations in intestinal cancer tissue and in colon and rectum polyps. *Biol Trace Elem Res*, Vol. 92, No. 1. Apr, pp. 1-10, Issn 0163-4984 (Print) 0163-4984

Diet and benign prostatic hyperplasia: A study in greece. *Urology*, Vol. 54, No. 2.

epithelium and stroma from human benign prostatic hypertrophic glands. *Prostate*,

MTF-1 mediates metal regulation of the mouse Znt1 gene. *J Biol Chem*, Vol. 275, No.

Leitzmann, M. F. (2007). Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP diet and health study. *J Natl Cancer Inst*, Vol. 99, No. 10. May 16, pp. 754-764, Issn 1460-2105 (Electronic) 0027-8874 (Linking) Leitzmann, M. F., Stampfer, M. J., Wu, K., Colditz, G. A., Willett, W. C. & Giovannucci, E. L.

(2003). Zinc supplement use and risk of prostate cancer. *J Natl Cancer Inst*, Vol. 95,

effect of zinc on human prostatic carcinoma cell growth. *Prostate*, Vol. 40, No. 3.

expression in human prostate normal vs. cancer cells: A time course study. *J Nutr Biochem*, Vol. 20, No. 12. Dec, pp. 1000-1012, Issn 1873-4847 (Electronic) 0955-2863

types of voltage-dependent ca2+ currents in rat palaeocortical neurons.

supplementation. *J Trace Elem Med Biol*, Vol. 20, No. 1. pp. 3-18, Issn 0946-672X

malignant tissues. *Cancer*, Vol. 52, No. 5. Sep 1, pp. 868-872, Issn 0008-543X (Print)

(2007). Acrodermatitis enteropathica and an overview of zinc metabolism. *J Am Acad Dermatol*, Vol. 56, No. 1. Jan, pp. 116-124, Issn 1097-6787 (Electronic) 0190-9622


Zinc Supplementation and Prostate Cancer 443

Tapiero, H. & Tew, K. D. (2003). Trace elements in human physiology and pathology: Zinc

Tenaud, I., Leroy, S., Chebassier, N. & Dreno, B. (2000). Zinc, copper and manganese

Tsui, K. H., Chang, P. L. & Juang, H. H. (2006). Zinc blocks gene expression of mitochondrial

Turgut, S., Kaptanoglu, B., Turgut, G., Emmungil, G. & Genc, O. (2005). Effects of cadmium

Uriu-Adams, J. Y. & Keen, C. L. (2010). Zinc and Reproduction: Effects of Zinc Deficiency on

Uzzo, R. G., Crispen, P. L., Golovine, K., Makhov, P., Horwitz, E. M. & Kolenko, V. M.

Uzzo, R. G., Leavis, P., Hatch, W., Gabai, V. L., Dulin, N., Zvartau, N. & Kolenko, V. M.

Vallee, B. L., Coleman, J. E. & Auld, D. S. (1991). Zinc fingers, zinc clusters, and zinc twists in

Vallee, B. L. & Falchuk, K. H. (1993). The biochemical basis of zinc physiology. *Physiol Rev*, Vol. 73, No. 1. Jan, pp. 79-118, Issn 0031-9333 (Print) 0031-9333 (Linking) Vartsky, D., Shilstein, S., Bercovich, A., Huszar, M., Breskin, A., Chechik, R., Korotinsky, S.,

Vlajinac, H. D., Marinkovic, J. M., Ilic, M. D. & Kocev, N. I. (1997). Diet and prostate cancer:

Wastney, M. E., Aamodt, R. L., Rumble, W. F. & Henkin, R. I. (1986). Kinetic analysis of zinc

Watjen, W., Benters, J., Haase, H., Schwede, F., Jastorff, B. & Beyersmann, D. (2001). Zn2+

West, D. W., Slattery, M. L., Robison, L. M., French, T. K. & Mahoney, A. W. (1991). Adult

Pt 1. Dec, pp. 2258-2262, Issn 0022-5347 (Print) 0022-5347 (Linking)

Aug, pp. R398-408, Issn 0002-9513 (Print) 0002-9513 (Linking)

Vol. 89, No. 4, Aug 2010, pp. 313-325, ISSN 1542-9741 (Electronic)

0753-3322 (Print) 0753-3322 (Linking)

609-615, Issn 0020-7136 (Print) 0020-7136 (Linking)

999-1003, Issn 0027-8424 (Print) 0027-8424 (Linking)

Winter, pp. 197-204, Issn 0163-4984 (Print)

1980-1990, Issn 0143-3334 (Print)

Issn 1078-0432 (Print)

(Print) 0959-8049 (Linking)

0300-483X (Print)

6705 (Linking)

and metallothioneins. *Biomed Pharmacother*, Vol. 57, No. 9. Nov, pp. 399-411, Issn

enhanced keratinocyte migration through a functional modulation of keratinocyte integrins. *Exp Dermatol*, Vol. 9, No. 6. Dec, pp. 407-416, Issn 0906-6705 (Print) 0906-

aconitase in human prostatic carcinoma cells. *Int J Cancer*, Vol. 118, No. 3. Feb 1, pp.

and zinc on plasma levels of growth hormone, insulin-like growth factor-1, and insulin-like growth factor-binding protein 3. *Biol Trace Elem Res*, Vol. 108, No. 1-3.

Prenatal and Early Postnatal Development. *Birth Defects Res B Dev Reprod Toxicol*,

(2006). Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: Implications for prostate cancer progression. *Carcinogenesis*, Vol. 27, No. 10. Oct, pp.

(2002). Zinc inhibits Nuclear Factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res, Vol. 8, No. 11. Nov, pp. 3579-3583,

DNA-binding protein domains. *Proc Natl Acad Sci U S A*, Vol. 88, No. 3. Feb 1, pp.

Malnick, S. D. & Moriel, E. (2003). Prostatic zinc and prostate specific antigen: An experimental evaluation of their combined diagnostic value. *J Urol*, Vol. 170, No. 6

A case-control study. *Eur J Cancer*, Vol. 33, No. 1. Jan, pp. 101-107, Issn 0959-8049

metabolism and its regulation in normal humans. *Am J Physiol*, Vol. 251, No. 2 Pt 2.

and Cd2+ increase the cyclic GMP level in PC12 cells by inhibition of the cyclic nucleotide phosphodiesterase. *Toxicology*, Vol. 157, No. 3. Jan 26, pp. 167-175, Issn

dietary intake and prostate cancer risk in Utah: A case-control study with special


Prasad, A. S., Mukhtar, H., Beck, F. W., Adhami, V. M., Siddiqui, I. A., Din, M., Hafeez, B. B.

Prasad, A. S., Schulert, A. R., Miale, A., Jr., Farid, Z. & Sandstead, H. H. (1963). Zinc and iron

Prost, A. L., Bloc, A., Hussy, N., Derand, R. & Vivaudou, M. (2004). Zinc is both an

559, No. Pt 1. Aug 15, pp. 157-167, Issn 0022-3751 (Print) 0022-3751 (Linking) Rishi, I., Baidouri, H., Abbasi, J. A., Bullard-Dillard, R., Kajdacsy-Balla, A., Pestaner, J. P.,

Ros-Bullon, M. R., Sanchez-Pedreno, P. & Martinez-Liarte, J. H. (1998). Serum zinc levels are

Samet, J. M., Graves, L. M., Quay, J., Dailey, L. A., Devlin, R. B., Ghio, A. J., Wu, W.,

Sandstrom, B. (1997). Bioavailability of zinc. *Eur J Clin Nutr*, Vol. 51 Suppl 1, Jan, pp. S17-19,

Schmitt, Y., Haug, M. & Kruse-Jarres, J. D. (1993). Determination of the trace elements zinc,

Shah, M.R., Kriedt, C.L., Lents, N.H., Hoyer, M.K., Jamaluddin, N., Klein, C. & Baldassare, J.

Shankar, A. H. & Prasad, A. S. (1998). Zinc and immune function: The biological basis of

Sharma, K., Mittal, D. K., Kesarwani, R. C., Kamboj, V. P. & Chowdhery. (1994). Diagnostic

Singh, K. K., Desouki, M. M., Franklin, R. B. & Costello, L. C. (2006). Mitochondrial aconitase

(Linking)

437-444, Issn 0002-9165 (Print)

0960-8931 (Print) 0960-8931 (Linking)

Issn 0954-3007 (Print)

0019-5359 (Linking)

558, Issn 0002-9513 (Print) 0002-9513 (Linking)

228, Issn 0931-2838 (Print) 0931-2838 (Linking)

Issn 1756-9966 (Electronic) 0392-9078 (Linking)

463S, Issn 0002-9165 (Print) 0002-9165 (Linking)

1073-8584 (Print) 1073-8584 (Linking)

& Kucuk, O. (2010). Dietary zinc and prostate cancer in the TRAMP mouse model. *J Med Food*, Vol. 13, No. 1. Feb, pp. 70-76, Issn 1557-7600 (Electronic) 1096-620X

deficiencies in male subjects with dwarfism and hypogonadism but without ancylostomiasis, schistosomiasis or severe anemia. *Am J Clin Nutr*, Vol. 12, Jun, pp.

intracellular and extracellular regulator of KATP channel function. *J Physiol*, Vol.

Skacel, M., Tubbs, R. & Bagasra, O. (2003). Prostate cancer in African american men is associated with downregulation of zinc transporters. *Appl Immunohistochem Mol Morphol*, Vol. 11, No. 3. Sep, pp. 253-260, Issn 1541-2016 (Print) 1533-4058 (Linking)

increased in melanoma patients. *Melanoma Res*, Vol. 8, No. 3. Jun, pp. 273-277, Issn

Bromberg, P. A. & Reed, W. (1998). Activation of mapks in human bronchial epithelial cells exposed to metals. *Am J Physiol*, Vol. 275, No. 3 Pt 1. Sep, pp. L551-

copper, nickel and chromium in bone marrow and plasma of patients with nonhodgkin lymphomas. *J Trace Elem Electrolytes Health Dis*, Vol. 7, No. 4. Dec, pp. 223-

(2009). Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer. *J Exp Clin Cancer Res*, Vol. 28, Jun 17, pp. 84,

altered resistance to infection. *Am J Clin Nutr*, Vol. 68, No. 2 Suppl. Aug, pp. 447S-

and prognostic significance of serum and tissue trace elements in breast malignancy. *Indian J Med Sci*, Vol. 48, No. 10. Oct, pp. 227-232, Issn 0019-5359 (Print)

and citrate metabolism in malignant and nonmalignant human prostate tissues. *Mol Cancer*, Vol. 5, No., pp. 14, Issn 1476-4598 (Electronic) 1476-4598 (Linking) Smart, T. G., Hosie, A. M. & Miller, P. S. (2004). Zn2+ ions: Modulators of excitatory and

inhibitory synaptic activity. *Neuroscientist*, Vol. 10, No. 5. Oct, pp. 432-442, Issn


**20** 

*USA* 

**The Role of Vitamin D in the Prevention** 

Prostate cancer is the most common non-cutaneous cancer in American men and the second most deadly (Jemal et al., 2010). One in six American men will get prostate cancer in his lifetime, and the risk increases with age. Prostate cancer progresses over the course of decades, so there is ample opportunity for prevention earlier in life. Epidemiological and laboratory studies point to vitamin D3 as a promising chemopreventative agent for prostate cancer. Vitamin D3 metabolites and analogs have been shown to induce cell cycle arrest, differentiation, and senescence in normal prostate cells and prostate cancer cells. Ongoing studies are interrogating the mechanistic effects behind vitamin D3 actions in the prostate. Additionally, clinical trials aim to investigate the potential chemopreventative and therapeutic effects of vitamin D3 metabolites and analogs, both alone and in combination with taxol-based chemotherapeutic agents. Herein we will summarize the epidemiological, laboratory, and clinical studies with vitamin D3 and the prostate and discuss how the current data supports a role for vitamin D3 in the prevention and

If prostate cancer is thought to be localized to the prostate and is classified as low-grade, "watchful waiting" is an option, since some prostate tumors do not become life-threatening. Otherwise, a prostatectomy or external beam radiation is the first line of therapy (or in some cases, brachytherapy). Both prostatectomy and radiation therapy can damage the nerves that rest along the prostate, so side effects include impotence and incontinence that may or may not reverse over time. If the cancer is thought to have spread beyond the prostate, then

Since androgens are required for growth of both normal prostate cells and most prostate cancer cells, androgen ablation therapy is standard in the forms of surgical or chemical castration. Castration has significant side effects, but it reduces tumor burden and metastatses and it can help ease pain from metastatic outgrowths. However, androgen deprivation therapy inherently selects for prostate cancer cells that can grow in the absence of androgens, which often leads to tumor recurrence in 18 to 24 months in the form of castration-resistant prostate cancer (Feldman & Feldman, 2001). The median survival time

**1. Introduction** 

treatment of prostate cancer.

**2. Prostate cancer treatment and prevention** 

a more systematic therapeutic approach is needed.

**and Treatment of Prostate Cancer** 

*University of Colorado, DenverAnschutz Medical Campus* 

Sophia L. Maund and Scott D. Cramer *Wake Forest University School of Medicine* 

emphasis on aggressive tumors. *Cancer Causes Control*, Vol. 2, No. 2. Mar, pp. 85-94, Issn 0957-5243 (Print)

